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ABSTRACT 
In the modern era, the most common post-operative complications following cardiopulmonary 
bypass (CPB) are neurocognitive deficits (NCD) and atrial fibrillation (AF). Both morbidities 
have been linked to inflammation resulting from surgery, anesthesia and CPB. Microemboli, 
inadequate oxygen delivery and the inflammatory response consequent to blood contacting 
artificial components of the CPB circuit have all been linked to postoperative NCD and to a 
lesser extent post-operative AF.  
The artificial components of the CPB circuit consist of stainless steel, polyvinylchloride 
(PVC), polycarbonate and other carbon-based plastics. In order to attenuate the negative sequelae 
of blood-circuit contact related inflammatory response, industry developed the biocompatible 
circuit (BCC) coating for the disposable CPB circuits. Four such coatings were studied and 
compared to an uncoated control group in a total of 101 patients undergoing routine CPB-
assisted cardiac surgical procedures.  Soluble adhesion molecule (SAM) activation was studied 
at different time points and common clinical outcomes such as white blood cell activation, serum 
renal function parameters urea and creatinine, postoperative bleeding, transfusion requirements, 
intensive care and hospital length of stay, CPB pump volume balances, changes in weight, 
postoperative serum lactate and glucose and the development of AF postoperatively, were 
compared.  Additionally, postoperative neurocognitive testing was performed using a simple 
bedside neurocognitive test called the antisaccadic eye movement test. The patients in all groups 
were tested for comparison preoperatively and 72 hr postoperatively.  
 
Results: The mandate of BCC coating development and manufacture is to attenuate the well-
documented and demonstrated inflammatory response consequent to the contact of blood with 
artificial CPB surfaces. The studied BCCs significantly decreased platelet transfusions in 
females. In addition, the BCCs decreased the concentrations of 2 SAMs when measured 6 hours 
after surgery and CPB. The difference in SAM expression seen between the coated and uncoated 
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groups at 6 hr was no longer apparent at 72 hr. Very little difference was noted between the four 
BCC groups.  
 
Patients who developed AF postoperatively seemed predisposed to do so as the serum levels 
of soluble vascular cell adhesion molecule was significantly higher at baseline and remained so 
at 6 and 72 hr. 
 
The decreased incidence of platelet transfusions in females, resulting from BCC use, is a 
highly significant finding within this higher-risk group of patients. As most platelet transfusions 
occur soon after the patient is disconnected from CPB, the short-term decrease in SAM 
activation can be linked to this improved clinical finding.  
 
The studied BCC coatings have achieved limited success in their intended mandate to 
attenuate inflammatory response in terms of improved clinical and laboratory desired outcomes. 
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1 LITERATURE REVIEW 
Many significant improvements have been achieved since the first successful combined 
clinical application of cardiopulmonary bypass (CPB) and cardiac surgery in 1953 (Gibbon, 
1954). Major technical, surgical and perfusion innovations have contributed to excellent current 
outcomes compared to the high incidence of morbidity and mortality incurred when the two 
interventions were in their infancy.  
CPB was initially developed to facilitate correction of congenital cardiac anomalies by 
providing a still, bloodless operative field (Gravlee et al. 2008). Surgical correction on a beating, 
fibrillating or inflow occluded heart was technically challenging in terms of time limitation, 
surgical exposure and surgical accuracy. Arresting the heart, while facilitating surgery, warrants 
adjunctive circulatory assist devices to provide for the metabolic demands of the body, thereby 
preventing ischemic injury (Gravlee et al. 2008). Extra corporeal circulation (ECC) in the form 
of CPB, powered by a heart-lung machine (HLM), was developed to maintain the systemic 
circulation long enough to allow for a controlled surgical correction. Chemical cardioplegic 
solutions, delivered by a secondary pump on the HLM, were later developed to arrest the heart 
while providing for its metabolic needs. Clinical experiments demonstrated enhanced cardiac 
muscle preservation during CPB when the heart was kept both, hypothermic and arrested 
(Gravlee et al. 2008). Decreased lactic acid formation meant the heart could easily resume 
regular contractions when needed. As CPB technology developed further and patient outcomes 
improved, usage of CPB expanded to include coronary artery bypass grafting (CABG), valve 
repairs, valve replacements and complex aortic reconstructions (Gravlee et al. 2008). 
 
1.1 CPB Circuit 
Definitive repair of congenital intra-cardiac malformations before 1953 was impossible. 
Development of the HLM is regarded as one of the most important medical inventions of the 
twentieth century (Gravlee et al. 2008). Surgical cardiac correction of congenital and acquired 
cardiac pathology once thought to be unattainable is now undertaken 2,000 times worldwide 
every 24 hr (Gravlee et al. 2008). Aptly named, the HLM takes over the function of the heart and 
the lungs while these organs are temporarily isolated from the systemic circulation. During this 
time, the HLM supports all cardiopulmonary supported metabolic demands of the body.  
The first successful attempt at cardiac surgery was the closure of an atrial septal defect in a 5-
year old girl. This was done under direct visualization using inflow occlusion and total body 
hypothermia (Lewis, 1953). This technique worked very well for simple repairs involving the 
atrium and pulmonic or aortic stenosis, but reinforced the need for a more comprehensive 
perfusion machine for more complex lesions (Swan et al. 1953).  
The first few attempts at using a HLM resulted in death (Gibbon, 1968). Death was due to an 
erroneous preoperative diagnosis in one instance and a massive air embolism in the other. The 
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perception at the time was that high systemic flows were needed to support the patient. This 
belief and the crude technology employed to oxygenate the blood lead to the fatal massive air 
embolus.  
Re-examination of previous animal studies lead to a reassessment of how much systemic flow 
was necessary to maintain basal metabolic demands (Hemmingway, 1913; Patterson, 1914). This 
new way of thinking brought hope to many working in the cardiac surgical field, as not only did 
the lower flows add an element of safety to the procedure, lower flows also meant there was less 
blood obstructing the surgical field (Helmsworth et al. 1953; Gibbon et al. 1954). Unfortunately, 
the necessary cannulation needed to connect the patient’s circulation to the HLM got in the way 
of the walnut sized pediatric hearts they were working on. This problem was alleviated by cross-
circulation technique, which permitted the cannulas to be placed out of the operative field 
(Cohen et al. 1953). The successful use of the cross-circulation technique used in dogs (whereby 
one dog’s circulation supported the other dog having the surgical correction) lead to the first of 
many successful procedures on children using the child’s parent, effectively, as the pump 
(Lillehei et al. 1955).  
In 1955, DeWall and Lellihei began using a disposal bubble oxygenator, which they had 
developed in their laboratory. As their successes mounted they began adapting the bubble 
oxygenator to meet the greater physiological demands of adult patients. The bubble oxygenator 
was eventually replaced by the safer and less disruptive microporous hollow fiber membrane 
oxygenator (Haworth, 2003).  
A further technical advance arrived with the proof that with induced hypothermia, 
hemodilution was permissible and in fact advantageous (Zuhdi et al. 1961). Not only did this 
effectively decrease the amount of blood needed for surgery (and its associated risks of 
immunologic sequelae and transmitted infection) but it also improved the quality of perfusion by 
decreasing the viscosity of blood (Zuhdi et al. 1961). When the patient’s circulatory volume is 
joined together with the CPB circuit, the patient’s blood volume is diluted with the 
crystalloid/colloid volume necessary to prime all the components and tubing. The initiation of 
CPB inevitably results in hemodilution of all cellular and non-cellular elements of the patient’s 
blood. 
During routine CPB-assisted cardiac surgical procedures, blood leaves the body from the right 
atrium through the venous cannula. Blood flows within the tubing, assisted by gravity drainage 
to a venous reservoir. Blood is then entrained from the venous reservoir and propelled by a 
mechanical roller pump (or a centrifugal pump) to the heat exchanger/oxygenator, arterial filter 
and lastly to the arterial cannula inserted into the ascending aorta. Artificial CPB circuit 
components are made up of various compounds which include polyvinyl chloride (PVC), 
polyester, silicon, stainless steel, polycarbonate, nylon, Anti-foam A©   (used as a defoamer for 
blood) and di-(2-ethylhexyl)phthalate, a plasticizer used to give flexibility to PVC tubing.  
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Under normal physiological circumstances, intravascular blood cells and proteins are only in 
contact with the endothelial lining of the vasculature. Upon immediate contact with the artificial 
surface of the disposable CPB circuit, a systemic inflammatory reaction of varying intensity 
dependent upon the patient and the CPB circuit occurs. Hemostasis, cellular metabolism and 
virtually all organ functions are affected (Day et al. 2005; De Mendonça-Filho, 2006; Braun et 
al. 2007; Vercaemst, 2008; Gravlee et al. 2008).  
 
1.2 CPB and Inflammatory Response  
The inflammatory/immune response generally protects organ systems against a host of 
noxious stimuli. Surgical wounds up-regulate the inflammatory response in order to promote 
necessary healing and recovery. However, the inflammatory response to CPB compounds the 
natural response from surgery. It is this excessive response, which can be harmful (Rubens el al. 
2004; Suleiman et al. 2008; Gravlee, 2008). It has been demonstrated that removing the stimulus 
from CPB (off-pump cardiac surgery, i.e., without CPB) results in a reduced inflammatory 
response in terms of significantly decreased cytokine levels with an associated decrease in the 
stress response (Suleiman et al. 2008). The majority of the stress response however is related to 
surgical trauma (Suleiman et al. 2008). Meta-analysis has yielded conflicting results. Raja and 
Dreyfus (2006) demonstrated decreased postoperative bleeding in patients undergoing off-pump 
CABG surgery. Parolari et al. (2009) and Seabra et al. (2010) suggest that when comparing 
short-term clinical outcomes between the two modalities, no statistical difference exists. Indeed, 
a meta-analysis reviewing long term results by Takagi et al. (2010) showed that incomplete 
coronary revascularization, which can result from CABG surgery off-pump, resulted in an 
increased risk of late mortality (more than one year after surgery). The solution then may be to 
continue to use CPB for most cardiac surgeries, but to continue to find ways to decrease the 
inflammatory response to the artificial environment introduced by the described CPB circuits.   
 
Two physiological protective immune response systems have been identified: innate and 
acquired. The innate system (nonspecific immunity) is made up of a host of phagocytic and 
endothelial cells (Mayer, 2007). Phagocytic cells function to engulf and ingest pathogens and 
cellular debris. Phagocytic cells can be blood-borne (monocytes and neutrophils) or in tissue 
(dendritic cells and mast cells). Neutrophils will be discussed in section 1.2.1.2. Monocytes in 
circulation are attracted to sites of inflammation through a process called chemotaxis (Bosco et 
al. 2008). Triggers of chemotaxis include damaged cells, pathogens and cytokines. Monocytes 
arriving at sites where inflammation is occuring, can differentiate and extravasate into tissue to 
become exudate-macrophages, exudate-resident macrophages and peroxidase-negative 
macrophages (Naito, 1993). These monocyte-derived macrophages are short-lived and non-
proliferating (Naito, 1993) whereas tissue, or resident macrophages can survive up to several 
months and can proliferate and self-regulate as needed. Macrophage characteristics depend upon 
the environment where they are found (Naito, 1993) and macrophage colony stimulating factors 
exist to activate genes important for macrophage differentiation (Naito, 1993). Resident 
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macrophages are named according to their location. Examples are dust cells, kupffer cells, 
osteoclasts and microglia found in the lung, liver, bone, and neural tissue, respectively (Liles and 
Van Voorhis, 1995). Monocytes can differentiate into dentritic cells found in external tissues 
such as the skin and the nose. Along with dendritic cells (Svensson et al. 1997), macrophages 
play a crucial role in initiating immune response. Their presentation of bits of antigen to other 
phagocytic cells such as helper T cells, results in the production of antibodies. (Bosco et al. 
862008). The antibodies quickly recognize the antigen upon second introduction allowing for 
easier engulfment by macrophages (Naito, 1993). Monocytes and macrophages produce 
monokines (a type of cytokine), following cell activation or damage. Examples of these are IL-1, 
IL-6, IL-8, IL-10, tissue necrosis factor (TNF) and interferons. All are important in regulating the 
immune response and inflammation (Wan et al. 1997). Natural killer cells are lymphocytes 
designed to destroy viruses and tumors by the granular proteins they release which cause 
apoptosis (Mayer, 2007). Innate immunity does not require prior exposure to be sensitized and 
activated. Soluble factors cytokines, complement, chemokines and acute phase proteins are 
always in circulation, prepared to protect their host when needed (Wan et al. 1997). The 
combination of surgical trauma, CPB and reperfusion injury of the heart and lungs following 
CPB results in the up-regulation and release of pro-inflammatory cytokines and stress-related 
hormones. These contribute to postoperative organ dysfunction by activating endothelial cell-
leukocyte adhesion and by promoting vascular inflammation (Franke et al. 2005). Stefano and 
Bilfinger, (1993) examining the effects of CPB using computer-assisted microscopic imaging 
measured a 48% increase in granulocyte and macrophage activation characterized by 
conformational changes and locomotion from pre CPB baseline cells. This group was able to 
conclude that though these cells exhibited heightened activation, they were later unable to 
respond to chemotactic agents post CPB. This is evidence leukocyte antibody production is 
impaired temporarily post CPB. 
Acquired immunity has memory based upon prior sensitization. Once the body generates an 
immune response to a specific antigen, acquired immunity becomes more efficient at destroying 
the known antigen upon next encounter. Vaccinations work in this manner. Antibodies and T and 
B-lymphocytes are the principle components of acquired immunity (Mayer, 2007). CPB-
generated inflammatory response, not being antigen-specific, cannot be attenuated or enhanced 
by repeated encounters. The ultimate goal remains to manufacture an immunologically inert 
surface for all blood contacting components of the CPB circuit. Such is the goal of biocompatible 
circuit (BCC) technology.  
BCCs were developed to minimize the inflammatory response occurring when blood comes 
into contact with the artificial surface. CPB is overwhelmingly noxious and analogous to turning 
the body inside out. The entire circulatory system is suddenly and intensely exposed to the 
unnatural environment and milieu of the CPB circuit. Negative manifestations of the 
inflammatory response to CPB can involve all organ systems (Day et al. 2005; De Mendonça-
Filho, 2006; Braun et al. 2007; Vercaemst, 2008) and although the intensity of individual 
response cannot be predicted, the magnitude of risk increases the longer a patient is supported by 
CPB (Kansy et al. 2010). Additional variable risk factors associated with CPB include 
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preoperative patient conditions (co-morbidities) and the amount of shed blood and microemboli 
returned to the circulation. Additionally, individual responses to heparin anticoagulation and 
protamine reversal vary. Results of logistic regression by Ferraris et al. 1996 linked the 
preoperative co-morbid state with postoperative morbidities due to the exacerbated inflammatory 
response from CPB  (Ferraris et al. 1996).  
Design of the CPB circuit plays a role in the intensity of the inflammatory response. Well-
designed circuits should not include any abrupt changes in diameter, direction or pressure as 
these can result in high shear stress and additional platelet activation and adhesion (Spijker et al. 
2003). CPB circuits should be as short as possible to minimize the blood/artificial surface 
interaction. Ideally the surface in contact with blood should be as non-reactive as the vascular 
endothelial lining. The components and tubing of the CPB circuit are PVC and other plastic 
composites. As these are reactive and not biological surfaces, BCCs have been developed to 
alleviate this. Certain developed BCC are heparin-based, which present a less thombogenic 
surface, while others incorporate natural endothelial proteins or inert molecules within their 
matrix in order to appear less foreign to circulating blood.  
Postoperative cerebral dysfunction was noted early on at the advent of CPB-assisted cardiac 
surgery and wide-ranging research has been conducted to understand and prevent this 
unfortunate occurrence (Hodges et al. 1958). It was noted that blood in contact with air (a 
consequence of the bubble oxygenators) resulted in air emboli formation, hemolysis and 
subsequent exacerbation of the inflammatory response to CPB (Hodges et al. 1958). The 
air/blood interface was greatly reduced with the advent of membrane oxygenators (Gravlee et al. 
2008). Additionally, air/blood interface can be minimized by decreasing the speed of the roller 
pump controlling the vent and cardiotomy suction thus preventing excessive amounts of air from 
being drawn in with the blood. Use of pump suction for scavenging shed blood should be 
discouraged. Excessive negative pressures (Hirose et al. 1964; Wielogorske et al. 1975; 
Gregoretti, 1996) and co-aspiration of air (Wright and Sanderson, 1979; de Jong et al. 1980; 
Gregoretti, 1996) attributed to cardiotomy suction contribute to hemolysis. The large raw surface 
area of the cardiac surgical wound, a primary site of thrombin generation, contains inflammatory 
cytokines, high concentrations of complement (C) 5a (a product of activated complement) and 
emulsified fat (Brooker et al. 1998; Wendel et al. 1999). Blood lost from the surgical wound 
often collects in the pericardial well and its contact with pericardium also contributes to 
hemolysis (Pierangeli et al. 2001). Consequently, blood which collects in the pleura should not 
be aspirated and returned to the CPB circuit but rather sent to an autologous transfusion device 
for processing before return to the patient. Alternatively, in times when bleeding is insignificant, 
this small amount of shed blood can be discarded. Universal practice of removing shed blood 
from the surgical field, where possible, reduces the inflammatory response by preventing 
thrombin, RBC castes and fat emboli from returning to the systemic circulation (Kincaid et al. 
2000; Pierangeli et al. 2001; Aldea et al. 2002). In a study by Skrabal et al. (2006), patients who 
had pericardial suction blood returned to the systemic circulation had significantly higher levels 
of C-reactive protein (CRP), PMN-Elastase, Interleukin (IL) -6, plasma free hemoglobin and 
lactate dehydrogenase. De Somer et al. (2002) found that aspirated woun
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by tissue contact showed a significant increase in plasma free hemoglobin and platelet activation 
resulting in a 30% increase in postoperative blood loss. Edmunds et al. (1978) and de Jong et al. 
(1980) found a correlation between the amount of cardiotomy suction used and the fall in 
circulating platelets.  
One of the most common postoperative complications of CPB is atrial fibrillation (AF). The 
direct link between AF, inflammation and hemodilution was first proposed upon realization that 
there was an increased incidence of AF two to three days post CPB (Bruins et al. 1997). This 
observed increased incidence of AF was associated with peak serum levels of CRP (Bruins et al. 
1997). Atrial biopsies showed inflammatory infiltrates suggesting oxidative damage and 
myocarditis (Frustaci et al. 1997; Mihm et al. 2001). Meta-analyses by Reston et al. (2003) and 
Athanasiou et al. (2003) comparing patients who underwent coronary revascularization surgery 
either with CPB or without (i.e., on-pump or off-pump), showed statistically significant 
reduction in AF among patients having undergone off-pump surgery. Meta-analyses by Ranucci 
et al. (2009) reviewing BCCs involving 36 randomized controlled trials and 4360 patients 
showed a decreased incidence of AF when BCC circuits were used. 
In summary, there are several logical strategies to decrease the inflammatory response to the 
commonly used uncoated CPB circuit; minimal use of cardiotomy suction and vent suction; 
intelligent circuit design (whereby the blood flow path through the CPB circuit is as gentle to 
cellular components as possible) and finally BCCs.  Medicinal anti-inflammatory prophylaxis 
techniques exist which include preoperative steroids, antifibrinolytics and non-steroidal anti-
inflammatory drug administration, to name a few. These prophylactic therapeutic strategies are 
beyond the scope of this paper. 
 
1.2.1 Cellular Inflammatory Components   
1.2.1.1 Erythrocytes 
The erythrocyte or red blood cell (RBC) (diameter 7 µm; number 5x106/µl), are supple and 
flexible, easily slipping through the smallest capillaries. Negative pressures generated from the 
vent and pump sucker, positive pressures generated by the roller pump and pressure excursions 
from blood flowing through the oxygenator and arterial filter exposes RBCs to considerable 
shear forces (Hirayama et al. 1985). These shear forces which result in mechanical or ionic pump 
damage, diminish the inherent deformability of the RBC. Hemolysis can result (Schmid-
Schönbein et al. 1979). Once the RBC membrane is altered, it is susceptible to attack by 
activated complement (Westaby, 1983). Adenosine diphosphate stores in the RBC are released 
into the plasma during cell lysis and may inadvertently alter platelet function resulting in 
decreased ability of the platelet to participate in hemostasis (Vercaemst, 2008). Tissue function 
may be affected when hemoglobin is no longer encased within the RBC membrane due to 
increases in plasma oncotic pressure and viscosity (Vercaemst, 2008). Accumulated RBC 
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membrane fragments (lipid ghosts) clog microcirculation and are important contributors of organ 
dysfunction (Yedgar et al. 2002; Vercaemst, 2008).  
Severe hemolysis results in a hypercoagulable state (Egeberg, 1962). In a study by van Beers 
et al. (2009), RBC-derived microparticles, correlating with markers of hemolysis, also strongly 
correlated with plasma markers of fibrinolysis (D-dimer) and coagulation activation 
(prothrombin fragment 1+2). Increased levels of these coagulation activation parameters and 
plasminogen activator inhibitor during CPB correlate with postoperative organ dysfunction 
demonstrated as decreased left-ventricular stroke work index, decreased PaO2/FIO2 ratio and 
increased serum creatinine levels (Dixon et al. 2005). 
 
1.2.1.2 Neutrophils/Leukocytes 
Leukocyte recruitment and activation within minutes of a noxious stimulus, coupled with their 
inherent cytotoxic capabilities, are central to an organism’s ability to fight off infection. 
Neutrophils are attracted to a site of infection by cytokines. These are expressed by activated 
endothelium, mast cells and macrophages. Neutrophils also express their own cytokines, which 
in turn recruit and amplify the reaction of other inflammatory cells (Mayer, 2007). Pus mostly 
made up of neutrophils bodies, is the evidence of death and destruction from the battles waged 
by neutrophils having migrated into the tissues to engulf invading pathogens. 
Neutrophils (12-15 µm) along with basophils and eosonophils, are frequently referred to as 
polymorphonuclear leukocytes, due to their multilobed nuclei. Neutrophils are generally the first 
of the inflammatory cells to arrive at a site of injury or infection (Cohen, 2002). They are 
efficient phagocytes of pathogens such as bacteria and fungi when coated with antibodies or 
complement. Their up-regulation by activated endothelium and sL-selectin is the main cause of 
systemic inflammatory response after CBP (Gravlee et al. 2008). Neutrophils, primarily 
stimulated by IL-8, interferon gamma and C5a in a process called chemotaxis, can also be 
activated by heparin, histamine, thromboxane A2, IL-1β, TNF and C5b-9 (Menasche et al. 2003; 
Warren et al. 2007). Neutrophil activation and adhesion can result in capillary blockage with 
localized ischemia (Anderson et al. 1987). Neutrophils once activated, can release their cytotoxic 
granular contents into the endothelium where direct cellular damage can result (Haga et al. 
1993). Neutrophil activation during CPB is evident by the loss of L-selectin, upregulation of 
complement receptor CD11b/CD18 (also known as macrophage-1 antigen), increased production 
of reactive oxygen species (ROS) and increased levels of neutrophil granular contents such as 
elastase (Haga et al. 1993; Gadaleta et al. 1994). 
Three types of neutrophil granules exist (Faurschou et al. 2003). Azurophil, or primary 
granules, function primarily within the cell and contain various proteases such as elastase, 
cathepsin G and proteinase (Faurschou et al. 2003).  Azurophils, contain antimicrobial agents 
such as myeloperoxidase, lysozymes, defensins and bactericidal permeability-increasing protein 
(Faurschou et al. 2003). The enzyme myeloperoxidase converts hydrogen peroxide into 
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hypochlorous acid a potent cytotoxic agent. Azurophils also contain acid hydrolases cathepsin B, 
cathepsin D, β-D-glucuronidase, α-mannosidase and phospholipase A2.  
Specific or secondary granules contain cell surface molecule receptors for C3b and 
chemoattractants. Specific granules initiate inflammation and contain soluble mediators C5 
component and macrophage chemotactic agents. Tertiary granules carry lysosomes as do primary 
and secondary granules. Lysosomes carry enzymes needed to digest all used up organic matter 
from phagocytosis, endocytosis and autophagy (Faurschou et al. 2003). 
Ongoing efforts to study and categorize the inflammatory response during CPB continue.  
Many researchers continue to compare on and off pump results in an effort to isolate the immune 
response to CPB alone. Work by Lin et al. on heat-shock protein 70kDa showed increased 
inflammatory response within leukocytes of patients undergoing CPB-assisted CABG compared 
to off-pump CABG (Lin et al. 2010). 
Work by Despotis et al. (1997) has shown positive correlation between increasing white 
blood cell (WBC) counts during CPB and patients most likely to bleed postoperatively. These 
increased numbers of WBC’s may be actively participating in fibrinolysis and clot instability by 
degrading fibrin with mediators elastase and cathepsin G. Alternatively, these increased WBC 
numbers may be simply signaling an exaggerated inflammatory response (Kolev et al. 2003). 
WBC counts were followed in the present study to determine if any of the BCC would be 
capable of attenuating their proliferation. 
Preventing neutrophil activation and adhesion during CPB by manner of removal of 
neutrophils by filtration (Whitaker et al. 2001), drug related down regulation (Chung et al. 2005) 
and/or BCC may result in decreased postoperative organ dysfunction and subsequently, an 
improvement in clinical outcomes. 
 
1.2.1.3 Neutrophils and Reperfusion Injury 
Reperfusion injury refers to the inflammatory response occurring when circulation returns to 
previously ischemic tissue beds. Ischemic injury occurs when perfusion is impaired. Ischemic 
cells will deplete their adenosine triphosphate stores by the action of hypoxanthine (Haga et al. 
1993). This initial cellular ischemia coupled with a lactic acidosis, altered cellular homeostasis 
and loss of cellular membrane ion gradients is amplified when blood flow is restored upon 
reperfusion (Gravlee et al. 2008). Phagocytes (neutrophils, monocytes and macrophages) 
increase their oxygen consumption, and manufacture leukotrienes (LT) (signaling molecules) 
and ROS (Haga et al. 1993; Gadaleta et al. 1994). Many fatty LT molecules exist such as LTA4, 
LTB4, LTD4, LTE4, and LTF4 (Stables et al. 2010).  Synthesis of LT occurs in the lipoxygenase 
pathway where there are produced from arachidonic acid in conjunction with 5-lipoxygenase. 
Cellular LT production enhances the reactivity of its host or that of neighboring cells thereby 
regulating the immune response. When these cells are activated, arachidonic acid, through a 
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series of enzymatic reactions and spontaneous reductions, converts to powerful chemoattractants 
(Stables et al. 2010). Chemoattractants (or conversely chemorepellents) are organic or inorganic 
substances, which attract or repel motile cells (Sallusto and Mackay, 2004). Effects of 
chemoattractants can be cell specific such as a ligand target and/or can be concentration 
dependent. Examples of chemoattractant receptors are CCR3, CCR4, CCR8 and CRTH2 
(Romagnani, 2002). 
This catalytic mechanism not only occurs in phagocytes, but also in mast cells, eosinophils 
and basophils. One of the functions of LT is to trigger smooth muscle contraction and their 
production is usually coupled with the production of histamine (Nelson and Cox, 2008). LT 
chemotactic effect on neutrophils is to recruit the necessary cells to regulate the inflammatory 
response, which frequently results in increased vascular permeability (Dahlen et al. 1981). 
ROS are a natural byproduct of metabolism. ROS participate in cell signaling leading to 
activation and transcription of genes relevant for cell growth and differentiation (Novo et al. 
2008). The effect of ROS on cells and tissues during periods of stress however, known as 
oxidative stress, can be quite damaging. Over a long period of time ROS can cause oxidative 
damage to DNA, proteins and lipids resulting in cancer, cardiovascular disease, type 2 diabetes, 
rheumatoid arthritis and neurodegenerative diseases (Novo et al. 2008). ROS are responsible for 
tissue injury because they oxidize or chlorinate molecular proteins and membrane lipids. ROS 
migration across cell membranes can lead to cell damage and apoptosis (Gadaleta et al. 1994). 
Major ROS include the superoxide anion (O2-), hydrogen peroxide (H2O2), hypochlorous acid 
(HOCl) (catalyzed by myeloperoxidase), hydroxyl radicals (OH-) and oxidation of other cellular 
molecules leading to new free radical species. Enzymes such as superoxide dismutase, 
lactoperoxidase, glutathione peroxidase and, importantly, uric acid exist to defend organisms 
from ROS through reaction with unpaired valence shell electrons (Gravlee et al. 2008; Novo et 
al. 2008). Inadequate tissue perfusion during CPB consequent to low systemic flows or linear 
flow situations (as opposed to normal pulsatile flow) can lead to tissue hypoxia and reperfusion 
injury. Additionally insufficient myocardial perfusion during the period of time where the aorta 
is crossclamped amplifies the resultant reperfusion injury occurring when normal blood flow to 
the coronary arteries is restored.  
 
1.2.1.4 Platelets 
Platelets are anucleate fragments of megakaryocytes possessing highly organized structures 
and glycogen energy stores (Cecil, 1993). At only 2-3 µm in diameter, the short-lived platelet 
plays a pivotal role in hemostasis. Clot formation could not occur without sufficient numbers of 
working platelets. Counts below 100,000/µl may result in an increased risk of bleeding (Cecil, 
1993). Platelet activation occurs due to binding of its membrane receptor GPIb to von 
Willebrand’s factor  (vWF). vWf is a large glycoprotein produced in subendothelial connective 
tissue and platelet alpha granules (Sadler, 1998). vWf and platelets present in plasma have high 
affinity to exposed collagen vWF, and tissue factor beneath the endothelial surface when there is 
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a vessel injury (Sadler, 1998). Collagen can anchor platelets at their receptor GPIa/IIa at one 
locus while simultaneously binding to GPVI at a second locus. In this manner, platelet binding 
and activation can occur simultaneously (Jaffe, 1994). Upon platelet activation, a physical 
transformation arises which exposes the previously covered receptor GPIIb/IIIa. Receptor 
GPIIb/IIIa can now bind with vWf multimers (one basic vWF monomer is 2050 amino acids 
(AA) and the platelet adheres firmly to subendothelial collagen (Sadler, 1998).  Activated 
platelets, once bound to the vessel wall, attract more of the same and stimulate vessel 
constriction. vWf, fibrinogen, tissue factor and C3a are potent stimulators of platelets 
aggregation (Wan et al. 1997; Sadler, 1998). These actions are crucial to arresting blood loss 
consequent to vascular damage. 
Not only are platelets critical for hemostasis but they also migrate to sites of injury and 
participate in the inflammatory response by secreting proinflammatory cytokines (TNF, cluster 
differentiation (CD) 40L and interleukin 1β) and chemokines monocyte chemotactic protein 1, 
CCL5 or RANTES and kCXCL4 or platelet factor 4) (Wagner et al. 2003). Activated platelets 
induce expression of monocyte chemotactic protein 1, and soluble intercellular adhesion 
molecule-1 (sICAM-1) on endothelium (Gawaz, 1998). This action prompts activation of 
endothelial nuclear factor-κB and nuclear factor-κB-regulated genes. NF-κB, induced by TNF, is 
a direct modulator of hypoxia inducible factors (van Uden et al. 2008). Hypoxia inducible factor 
promotes glycolysis and angiogenesis (Wong et al. 2008). Consequently, activated platelets 
promote the early onset of inflammation in atherogenesis. 
Other pro-inflammatory factors released from platelets include serotonin, bradykinin, 
prostaglandins, prostacycline, thromboxane and histamine, all functioning to increase cell 
proliferation and migration to the injured area to support healing (Stadelmann et al. 1998). 
Adhered platelets also support leukocyte rolling, adhesion and transmigration through the 
endothelium and into the affected tissue (Sadler, 1998).  
The pump sucker is a surgical convenience associated only with CPB-assisted cardiac 
surgery. Systemic heparinization delays shed blood from clotting. Consequently, this blood can 
be aspirated from around the wound, returned to the HLM, filtered by the cardiotomy reservoir 
and returned to the circulation. Blood contacting injured vessels or the CPB circuit causes 
platelets to aggregate together. Platelets will also aggregrate with fibrin, monocytes and 
neutrophils (Gorbet et al. 2004; Edmunds et al. 2006). Once again falling platelets counts are 
often consequent to long CPB times and excessive use of the pump sucker (de Jong et al.1980; 
Kansy et al. 2010).  
Platelet aggregation and sequestration can occur within the currently employed membrane 
oxygenators leading to oxygenator failure. This rare but serious complication requires stopping 
CPB and immediately replacing the defective component for another. Platelet sequestration 
interrupts the blood path within the oxygenator leading to large changes in pressure, excessive 
shear stress, hemolysis and possibly compromised gas exchange (Myers et al. 2003). 
Postoperative platelet transfusions may be required. 
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Excessive pressure gradations became an unwanted complication when albumin was removed 
from CPB priming solutions (Gu et al. 2006). Vendors have maintained that the push for 
biocompatible coatings came as a response to the high changes in pressure occurring when 
albumin was removed from the prime (B. Klanke, personal communication, May, 2009). To its 
credit, BCC have almost completely eliminated this unwelcome complication (Marcoux, 2009).  
The unavoidable activation of platelets throughout CPB results in compromised hemostasis 
postoperatively. CPB-assisted cardiac surgery should be completed as quickly and efficiently as 
possible as duration of CPB correlates with the extent of platelet destruction and postoperative 
bleeding (Wahba et al. 1996; Greilich et al. 2002). 
 
1.2.1.5 Endothelial Cells 
Endothelial cells form a single layer of simple squamous epithelium within the vasculature. 
Endothelial cells regulate the movement of fluid into and out of circulation while providing a 
non-thrombogenic surface for blood to come in contact with. Endothelial cells are also involved 
in the entrapment of leukocytes via expression of surface proteins and soluble adhesion 
molecules (SAM) whenever a vessel is injured (Laffey et al. 2002; Colman et al. 2006). 
Hypoxia, surgical manipulation and the artificial CPB circuit activate endothelial cells (Gravlee 
et al. 2008). Circulating thrombin, proinflammatory cytokines, C5a, and oxidants become 
stimulated and in turn activate the SAMs soluble endothelial-selectin (sE-selectin), sICAM-1, 
and soluble vascular cell adhesion molecule 1 (sVCAM-1). SAMs function to capture circulating 
leukocytes and assist their transport through the endothelium into the interstitial space.  
Endothelial cells produce many of the protein factors and molecules critical to the balance of 
the homeostatic thrombotic status. These molecules include adhesive proteins such as the 
integrins, cadherins and selectins, vWf, protein S, tissue factor pathway inhibitor, tissue 
plasminogen activator, urokinase plasminogen activator, plasminogen activator inhibitor and 
heparan sulphate (Colman et al. 2006). Endothelial cells also produce many vasoconstrictive and 
vasodilatory molecules such as nitric oxide, histamine, norepinephrine and bradykinin (Colman 
et al. 2006). Linear flow and embolic generation resulting from CPB change homeostasis 
activating endothelial cells. The resulting thrombin formation, fibrinolysis and acute 
inflammation, increases endothelial cell permeability and leukocyte migration into the interstitial 
space (Colman et al. 2006). Clinically this is manifested by tissue edema. 
 
1.2.1.6 SAMs  
Soluble adhesion molecules, briefly discussed under heading 1.2.1.5 Endothelial cells, play 
an integral role in the immune response. Elevated levels found in circulation are evidence of a 
heightened inflammatory response. Molecules are known as sVCAM-1, sICAM-1, sE-selectin, 
soluble leukocyte selectin (sL-selectin) and soluble platelet selectin (sP-selectin). sICAM-1 and 
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sVCAM-1 are members of the immunoglobulin superfamily (IgSF). The selectin family E, L and 
P, are so named because they include lectin adhesion molecules in their structure (Alexander, 
1994). Lectins are proteins that bind sugar polymers (Parham, 2005). The identifying letter 
before selectin refer to where these SAM can be found: endothelium, leukocytes and platelets, 
respectively. Cytokines such as TNF and IL-1 are responsible for excitation of most SAMs. 
SAMs can only be detected in soluble form in circulation. Elevated levels have been linked to 
dyslipidemia, atherosclerosis (Hackman, 1996) connective tissue disorders and some cancers 
(Blann, 1999). Long-term prospective study results from meta-analyses undertaken by Danesh et 
al. (1998) and Ross et al. (1999) have determined a link between elevated mononuclear cells, 
CRP and coronary heart disease (CHD). Additionally, there is a strong association between CHD 
and elevated serum levels of sICAM-1 and sE-selectin (Hwang, 1997; Ridker, 1998). Cell 
adhesion molecules sICAM-1 and sVCAM-1 are found in higher concentrations in individuals 
with atherosclerotic vessel walls compared to healthy endothelial tissue (Poston, 1992; Davies, 
1993). sICAM, sVCAM-1 and sE-selectin have been found in elevated levels in obese, 
hypertensive and diabetic children.  SAMs and endothelial activation appear related to the 
earliest stages of atherosclerosis (Glowinska et al. 2005). Elevated levels of sICAM-1, sVCAM-
1 and sL-selectin have been found in patients with obstructive sleep apnea syndrome (Ohga et al. 
1999). 
Just as elevated levels of SAMs have been found in patients with atherosclorosis, they have 
also been associated in patients with chronic AF (Blann, 1999; Roldán, 2003). Upregulation of 
monocyte adhesion receptor CD11b, and increased levels of circulating monocytes and 
neutrophils, are also associated with an increased incidence of postoperative AF (Fontes et al. 
2005). As the BCCs boast anti-inflammatory properties, examining SAM expression and their 
association with AF beg comparison among the tested circuits. 
Multiple studies have compared the effects of BCC on SAM release (Schreurs, 1998; 
Andresen, 2002; Alex, 2003; Bical, 2006). Studies have also compared SAM expression 
differences between on-pump and off-pump cardiac surgery. To date there are no studies 
comparing the release patterns of sVCAM-1, sICAM-1, sE-selectin and sL-selectin with respect 
to the four BCCs included in this study.  
 
1.2.1.6.1 sVCAM-1 
 VCAM-1 is also known as CD106. CD refers to a human gene and the protein it encodes 
(Carlson et al. 1988). At approximately 100-110 kDaltons, VCAM-1 is a transmembrane 
glycoprotein with seven C-2 type immunoglobulin domains (Cybulsky et al. 1991). All IgSF 
proteins possess variable domains named after the immunoglobulin (Ig) molecules. They are 
categorized according to size and function (Barclay, 2003). The seven C-2 type Ig domains 
mentioned above, refer to variability and number of beta strands forming the sandwich like 
structure characteristics of Ig domain (Harpaz et al. 1994). VCAM-1 is composed of 715 AA. 
Most of this molecule (677 AA) is normally found in the extracellular space. Twenty-two AA are 
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found in the transmembrane segment. Nineteen AA are found in the tail sitting in the cytoplasm 
of its host cell (Imhof et al. 1995). Multiple N-linked glycosylation sites sit in the extracellular 
region where every C2-Ig domain is capped by a disulphide bridge (Imhof et al. 1995). Soluble 
VCAM-1 has been identified in blood, culture supernates and cerebrospinal fluid (Pigott et al. 
1992). Neurons, fibroblasts, macrophages, endothelial cells and smooth muscle cells have all 
been found to express VCAM-1 (Imhof et al. 1995).  
VCAM-1 plays an important role in attaching lymphocytes, eosinophils, basophils and 
monocytes to the endothelial cells (Imhof et al. 1995).  The soluble ectodomain of VCAM-1 
(sVCAM-1) is proteolytically released from the endothelial cell surface into circulation in 
response to proinflammatory cytokines (Morisaki et al. 1995), (Singh et al. 2005).  Cytokines 
actively involved in proteolysis of VCAM are TNF, IL-1α and IL-1β, IL-4, and IL-13 (Morisaki 
et al. 1995), (Singh et al. 2005). Heightened VCAM-1 activation can last up to 24 hr and 
elevated VCAM-1 shedding levels can be observed within 8 hr of cytokine stimulation (Singh et 
al. 2005). Cytokine stimulation increases cell surface expression of VCAM-1, which makes it 
more approachable by proteases (Singh et al. 2005).  
VCAM-1 binds to two types of integrins: α4β1 (VLA-4) and α4β7 (LPAM-1). Both are 
expressed on all leukocytes except neutrophils (Koisumi et al. 1995; Sudhoff et al. 1996). The 
above integrins are also known as VCAM-1 ligands. “VCAM-1 to VCAM-1” ligand interactions 
are thought to be the stimulus required for leukocyte extravasation (Imhof et al. 1995).  It is also 
thought that VCAM-1 (and ICAM-1) regulates osteoclastogenesis via cell-to cell contact 
mechanism (Fujii et al. 2003) and the induction of sickle cell adherence to vascular endothelial 
cells during hypoxemia (Klings et al. 2008).  
Elevated sVCAM-1 levels have been found in the serum of patients with rheumatoid arthritis 
(Croft et al. 1999) systemic lupus erythematosus and multiple sclerosis (Baraczka, 2001). 
Elevated levels found in the cerebrospinal fluid of patients with intracerebral bleeds have been 
associated with poor clinical outcomes (Kraus, 2002). Elevated levels have also been found in 
myelomonocytic leukemia (Sudhoff et al. 1996) and bronchial asthma (Koisumi et al. 1995). The 
intensity of sVCAM-1 expression correlates with the magnitude of the inflammatory response 
(Croft et al. 1999). Normal circulating levels of sVCAM-1 are below 1012 ng/mL (Papayianni et 
al. 2002).  
 
1.2.1.6.2 sICAM-1 
ICAM-1 (also known as CD54) is a 90 kDalton cell-surface glycoprotein active in regulating 
leukocyte migration and activation (Yang et al. 2005). Found almost everywhere in the body, 
ICAM-1 is activated at sites of inflammation by cytokines (IL-1 and TNF) on macrophages, 
lymphocytes, endothelial and epithelial cells (Yang et al. 2005). ICAM-1 mediates the adhesion 
and paracellular migration of leukocytes expressing lymphocyte function-associated antigen 1 
and membrane attack complex (Marlin et al. 1987; Riet et al. 1993). This important adhesion 
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molecule promotes angiogenesis, T cell proliferation and cytokine release while prolonging 
antigen release by dentritic cells. sICAM production is due to proteolytic cleavage (Budnik et al. 
1996). 
Found in urine, bronchoalveolar lavage fluid, cerebrospinal fluid and serum, elevated levels of 
sICAM indicate vascular endothelial cell activation or damage and are associated with 
cardiovascular disease, hypertension, type II diabetes (Morisaki et al. 1997) sepsis (Nakae et al. 
1996) and obesity (Nelson et al. 2007). Normal levels of sICAM are <206 ng/mL (Sano, 1994; 
Wu et al. 2003; Alexandrakis et al. 2004). 
 
1.2.1.6.3 sE-selectin 
E-selectin is a 115 kDalton transmembrane glycoprotein. Also known as endothelial 
leukocyte adhesion molecule-1 or CD62E, E-selectin is only present on endothelial cell 
membranes. E-selectin is transiently expressed 6 hours after activation by inflammatory 
cytokines (IL-1β or TNF), or endotoxins (Lidington et al. 2002). Along with L and P-selectin, it 
contributes to leukocyte adhesion onto endothelium. Maximum expression occurs six hr after 
stimulation after which E-selectin is released into the vascular space. Finding elevated levels of 
sE-selectin in the blood is a sign of endothelial activation (Gearing et al. 1993).  
At the site of inflammation, E-selectin mediates the rolling attachment of leukocytes 
(neutrophils, monocytes and memory T-cells) to the endothelium, a crucial step in extravasation 
of the leukocyte (Banks et al. 1993; Cummins et al. 1997). sE-selectin, perpetually present in the 
blood of healthy individuals arises from proteolytic cleavage of the surface expressed molecule. 
Certain pathological conditions such as sepsis, systemic inflammatory response syndrome 
(SIRS) and hemodynamic compromise, result in elevated circulating levels (Cummins et al. 
1997). E-selectin has proinflammatory and angiogenic properties as well (Sezer et al. 2000). 
Normal serum levels of sE-selectin are below 29 ng/mL (Alexandrakis et al. 2004). Higher than 
normal levels of sE-selectin result in enhanced microvascular permeability and tissue edema.  If 
the edema is excessive and remains unchecked, tissue ischemia and necrosis are possible 
consequences (Visser, 2006). 
 
1.2.1.6.4 sL-selectin 
L-selectin has been given many names since its discovery: CD62L, leukocyte adhesion 
molecule-1, leukocyte endothelial cell adhesion molecule, DREG, MEL-14 antigen, TQ1, Leu-8 
and lymph node homing receptor (Cotran, 1998). This single-chain transmembrane glycoprotein 
is expressed by granulocytes, lymphocytes, and monocytes (Cotran, 1998). Two types of L-
selectin have been identified; one is found on lymphocytes and has a relative mass of 74 
kDaltons and the other is found on neutrophils and is 90-110 kDaltons (Cotran, 1998). L-selectin 
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is composed of an amino-terminal calcium dependent lectin section (Cotran, 1998). Along with 
its large transmembrane section, L-selectin has a short section extending into the cytoplasm 
(Ivetic et al. 2004). In areas of acute or chronic inflammation, these SAMs aid extravasation of 
neutrophils and leukocytes into the surrounding tissues and lymph nodes (Ivetic et al. 2004). L-
selectin in concert with P-selectin mediates the initial contact with circulating leukocytes which 
starts them rolling along the endothelial surface. A secondary, stronger reaction involving L-
selectin and E-selectin leads to the extravasation through the vessel endothelial wall into the 
inflamed lymphoid tissues (Cotran, 1998; Ivetic et al. 2004; Parham, 2005).  
Leukocytes cannot participate in inflammatory response unless they are activated. Treatment 
of neutrophils with phorbal esters and chemotactic factors results in down-regulation of L-
selectin surface expression followed by shedding of sL-selectin from the neutrophil (Jutila et al. 
1989). The corresponding increase in the now measurable soluble version of L-selectin inhibits 
neutrophil migration to areas of inflammation (Jutila et al. 1989; Kishimoto et al. 1989). In other 
words, circulating sL-selectin in high enough concentrations is thought to inhibit the binding of 
neutrophils and lymphocytes to the endothelium. When L-selectin is shed off the neutrophil, the 
neutrophils cannot deform and become activated. The same occurs in regards to L-selectin and 
lymphocytes (Jung et al. 1990). Ergo, shedding of L-selectin limits inflammation of leukocytes 
(Hafezi-Moghadam et al. 2001). The average plasma levels in healthy adults ranges between 1-6 
µg/mL (Tu et al. 2002). High and low concentrations of sL-selectin have been found in healthy 
and unhealthy subjects suggesting that sL-selectin must be present to a certain degree for 
leukocyte extravasation to occur (Smalley et al. 2005). Leukocyte attachment to cytokine-
activated endothelium is completely inhibited at sL-selectin concentrations of 8-15 µg/mL 
(Schleiffenbaum et al. 1992). 
 
1.2.2 Humoral Inflammatory Components 
1.2.2.1 Complement 
More than 30 proteins make up the primary recognition system and effector immune response 
of the complement activation system (Paul, 1999). Complement functions include controlling 
inflammation, opsonization of antigenic particles/molecules and pathogen membrane disruption 
(Paul, 1999).  Individual elements of complement react with each other whereby an enzyme 
created by one reaction can in turn go on to stimulate another. In this manner, a small initial 
stimulus can be amplified to bring forth destruction of an invading pathogen. The complement 
system has three different pathways (classical, alternative and lectin). The classical system is 
upregulated by antibody/antigen binding on cell surfaces. The alternative system is upregulated 
either as a product of the classical system or by surfaces presented by viruses, bacteria and the 
CPB circuit. The lectin system though similar to the classical system, is activated by mannose-
binding lectin, and ficolins attaching to pathogen surfaces (Gravlee et al. 2008). All three 
pathways terminate in a similar fashion by forming the membrane attack complex. The 
membrane attack complex can lyse through the membrane of the offending invader allowing an 
influx of ions and water into the cell, potentially leading to cell lysis.  
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During CPB and for a short time thereafter, complement activation occurs mainly by the 
classical and alternative pathways (Levy et al. 2003). Blood contact with the artificial surface is 
the primary stimulus for alternative pathway stimulation leading to the formation of 
anaphylatoxins C3a and C5a (Wan et al. 1997; Gorbet et al. 2004). These stimulate the release of 
histamine from mast cells and basophils increasing vascular permeability. C3a and C5a also 
stimulate the release of oxygen free radicals and lysosomal enzymes from WBC. Protamine 
neutralization of heparin post CPB can activate the classical pathway leading to an associated 
rise in C4a and a further rise in C3a. (Wan et al. 1997). Histamine release, and generalized 
inflammation follow (Miller et al. 1997). Consequently, organ dysfunction after CPB is 
primarily due to complement and neutrophil interaction (Edmunds et al. 2006; Edmunds et al. 
2008). 
 
1.2.2.2 CPB and Coagulation  
Endothelial cells provide a nonthrombogenic surface. The delicate balance existing between 
procoagulants and anticoagulants is disrupted when blood contacts the ECC (Nieuwland et al. 
1997). CPB intensifies thrombosis and would therefore not be possible without large systemic 
anticoagulant doses of heparin. Heparin is readily isolated from bovine lung and porcine 
intestinal mucosa (Rodriguez et al. 1979). Although not the ideal anticoagulant because it does 
not completely prevent thrombin formation, it is easily reversed with protamine sulphate and it is 
inexpensive to manufacture. Heparin greatly enhances the affinity of antithrombin III for 
thrombin (Rosenberg, 1989). Once bonded to antithrombin III, thrombin is unavailable to cleave 
fibrinogen into fibrin. Long unfractionated strands of heparin inhibit thrombin and, to a lesser 
extent, factors Xa, IXa, XIa, XIIa kallikrein and plasma (Pixley et al. 1985). Inactivated by 
heparin, thrombin can no longer activate factors VIII and V, which serve to accelerate the rate of 
fibrin formation (Hill-Eubanks et al. 1989).  
Thrombin generation can also occur when platelets, monocytes, neutrophils and endothelial 
cells are activated by the enzymatic responses to CPB (Nieuwland et al. 1997). Continuous 
formation of thrombin throughout CPB despite relatively high doses of systemic heparin 
administration results in a consumptive coagulopathy (Gravlee et al. 2008). The longer a patient 
is supported by ECC the more coagulation proteins are consumed in an endless anti-
thrombotic/prothrombotic cycle. Bursts of thrombin and fibrinogen generation occur when 
initiating CPB and again upon reperfusion of the previously ischemic myocardium (Chandler and 
Velan, 2003). Fibrin and thrombin generation return to baseline levels 2 hours after the 
conclusion of CPB (Chandler and Velan, 2003). Coagulation and inflammation are intricately 
tied together as one pathway feeds back to the other and vice versa (Ott, 2005).  
Two pathways of the coagulation cascade lead to fibrin formation: the contact activation 
pathway (intrinsic) and the tissue factor pathway (extrinsic). Of the two pathways, tissue factor 
(also known as FIII, tissue thromboplastin and CD142) appears most important because 
individuals deficient in contact activation proteins who undergo CPB do not experience 
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excessive postoperative bleeding (Burman et al. 1994). Exposure of blood to tissue factor, only 
present when the endothelium is breached, results in an immediate response by circulating 
platelets and plasma coagulation proteins (Furie et al. 2005). Tissue factor immediately binds 
with readily available factor VII. Tissue factor and factor (F) VII complex activates FIX and FX. 
Activated FX and its co-factor activated FV form a prothrombinase complex serving to activate 
prothrombin to thrombin. Thrombin then goes on to catalyze FV to activated FV, FVIII to 
activated FVIII and platelets (Colman et al. 2006).  
The contact activation pathway involves high-molecular-weight kininogen, prekallikrein, 
FXII and FXI. The contact activation pathway and the tissue pathway once activated, come 
together to form the common pathway resulting in the cross-linked fibrin clot. 
Three reversible alterations in coagulation typically occur during the clinical application of 
CPB: systemic heparinization, hypothermia and hemodilution. Heparin, though completely 
necessary for anticoagulation, has an unfortunate secondary antiplatelet effect by binding to vWf 
at platelet receptor GPIb. As well, inadequate protamine sulphate administration following CPB 
can result in continuing heparin anticoagulation interfering with hemostasis. Additionally, 
heparin bound to protein can become unbound following CPB and can contribute to 
postoperative bleeding. This occurrence, known as heparin rebound, is a frequent postoperative 
complication observed in the intensive care unit after the patient’s arrival from the operating 
room.  
Hypothermia has been shown to decrease the speed of enzymatic reactions. For every 10°C 
decrease in temperature, a concurrent 50% decrease in metabolic rate occurs (Kirkland and 
Barratt-Boyes, 1993). Consequently, enzymatic activity driving the soluble coagulation cascade 
is adversely affected (Wolberg et al. 2004). Above 33°C activity of the clotting factors is 
minimally reduced, however, below 33°C platelet adhesion and aggregation are significantly 
impaired (Watts et al. 1998). Thankfully, hypothermic impairment of coagulation and platelet 
activity can be reversed with adequate warming of the patient to 37°C. Inadequate warming or 
inadvertent cooling once the patient is separated from bypass frequently occurs as the chest 
cavity may be exposed to the cooler temperatures typical of most operating rooms, contributing 
to postoperative hemorrhage.  
The necessary combination of the CPB circuit prime (crystalloid and colloid) with a patient’s 
circulation results in the hemodilution of patient’s cellular blood components. The degree of 
hemodilution is dependant upon the priming volume of the circuit, size and volume status of the 
patient, and degree of preoperative anemia. Average human blood volume is equivalent to 5 
liters. The volume required to prime the CPB circuit at our institution is 1.8 liters. Therefore the 
resultant hemodilution is 36%. Davidson et al. (2003) measured coagulation factors changes 
induced by hemodilution and CPB. They concluded that FVIII concentration was barely affected 
whereas, FII and FX decreased by more than 50% (Davidson et al. 2003). Thrombin potential 
(amount of thrombin able to be formed in plasma measured in nmol/L) was also decreased by 
50%. This study suggests that, the consequence of simultaneous multiple factor deficiencies 
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result in greater decreases in thrombin generation as compared to what would occur if only one 
factor out of the many was deficient (Gravlee et al. 2008). 
The longer a patient is supported by a HLM the greater the risk of post-operative 
coagulopathy. After more than 3 hr of time spent on a HLM (time dependant on many clinical 
factors), a demonstrable decrease in the patient’s ability to make effective clot occurs (Kansy, 
2010) in spite of adequate rewarming and heparin reversal. 
 
1.3 CPB and Organ Dysfunction  
Postoperative organ dysfunction is uncommon and usually temporary after routine CPB-
assisted cardiac surgery (Gravlee et al. 2008). Organs most commonly affected are the kidneys 
and the brain (Gravlee et al. 2008). There is a positive correlation between microemboli 
production and postoperative organ dysfunction (Westaby, 1987). Production of microemboli 
during CPB whether due to air, fibrin emboli, macroaggregates of platelets, leukocytes, fat 
globules, foreign material or RBC fragments, are directly proportional to the amount of time a 
patient is supported by the HLM (Blauth, 1995; Hessel, 2003). Particulate emboli aspirated from 
the wound by the cardiotomy suckers, are the primary source of microemboli formation 
(Brooker, 1998; Hessel, 2003). Aspiration of shed blood mixed with air will generate 
microbubbles (Blauth, 1995) while surgical manipulation of the atheromatous aorta may generate 
solid emboli (Blauth, 1995). Most postoperative organ dysfunction is likely due to a combination 
of factors involving microemboli and the previously mentioned inflammatory response. 
 
1.3.1 CPB and Renal Function  
Postoperative renal failure, defined as an increase of serum creatinine by 25% from baseline 
(Brown et al. 2006), is uncommon (1%) following routine cardiac surgery in patients with 
normal, preoperative kidney function. This undesired side effect has been linked to CPB, 
hemolysis, inadequate perfusion, microemboli and inflammation (Liu et al. 2000). In the 
presence of preoperative kidney dysfunction, the risk of postoperative renal failure increases to 
20% (Liu et al. 2000). Creatinine present in the blood as a by-product of muscle breakdown is 
mostly filtered without absorption. Therefore any increase in circulating creatinine is indicative 
of a decrease in glomerular filtration rate (Stevens et al. 2006).  
Glomerular filtration rate is largely dependent upon blood pressure despite a certain amount 
of existing autoregulation. Increased blood pressure can result in a significant increase in urine 
output while a mean arterial pressure as low as 50 mmHg will have the opposite result (Gravlee 
et al. 2008).  
Perioperative risk factors associated with postoperative renal dysfunction include congestive 
heart failure, diabetes mellitus, previous coronary artery bypass grafting, elevated preoperative 
creatinine, CPB times longer than 3 hr, low cardiac output, hypovolemia, excessive 
 
 
 
 
 
 
 
19 
hemodilution, age greater than 70, and renal emboli (Mangano et al. 1998). Thirty day mortality 
for patients requiring dialysis following cardiac surgery and CPB is increased to 63% in 
comparison to an accepted mortality of 0.9% for elective patients not afflicted with postoperative 
renal dysfunction or other significant co-morbidities (Mangano et al. 1998).  
Neutrophil activation as a component of systemic inflammatory response syndrome has been 
implicated as a cause of perioperative renal dysfunction (Rinder et al. 2003; Stallwood, 2004). 
Significant hemolysis can lead to glomerular dysfunction and damage from the RBC casts 
(Yedgar et al. 2002). Certain intra-cardiac surgical procedures such as valve repairs or 
replacements can result in excessive use of the pump sucker for return of shed blood into the 
systemic circulation. Hemoglobinuria is due to fragmented RBC filtration through the 
glomerulus. This phenomenon is manifested in a reddish tinged urine production. 
 
1.3.2 CPB and the Brain 
Major surgery with or without CPB can result in a wide spectrum of neurologic injury, 
especially in the elderly population (Moller et al. 1998). Risks are proportionally greater for 
cardiac surgical patients because many have preexisting risk factors for stroke and cognitive 
impairment (Gravlee et al. 2008). These risk factors include advanced age, aortic atherosclerotic 
disease, carotid stenosis, previous/recent myocardial infarction, atrial arrhythmias, hypertension, 
diabetes and previous neurological events (Newman et al. 1995). Technological and surgical 
advancements have reduced the risk of stroke to 3-8% but the incidence of neurocognitive 
deficits (NCD) at hospital discharge (10-80%) and at 3 months and 6 months are higher (5-20%) 
(Newman et al. 2001). All 261 patients in the above mentioned study by Newman et al. (2001) 
were free of any history of cerebrovascular disease, renal disease and active liver disease prior to 
undergoing cardiac surgery.  
 
Microemboli and macroemboli are introduced to all patients at some point during CPB and 
cardiac surgery (Stump et al. 1996). As previously described, they originate from aortic 
atheromas, cellular debris (leukocyte and platelet-fibrin aggregates) and air microbubbles 
generated by the HLM and surgical field (Pugsley et al. 1994). Most overt strokes are associated 
with surgical/physical manipulation of the aorta (Pugsley et al. 1994). Widespread cerebral 
microembolizations are likely the primary mechanism of NCD while the ensuing inflammatory 
process likely exacerbates the magnitude of injury (Beamer et al. 1995; McKeating et al. 1998; 
Pantoni et al. 1998). 
 
Hypertension and diabetes are independent risk factors for postoperative brain injury in 
cardiac surgery. The mechanism of injury in this group is likely the result of regional cerebral 
hypoperfusion (Oliveira et al. 2008) and previously mentioned microembolization. Degenerative 
vascular changes means that blood flow is critically dependent on perfusion pressure rather than 
vascular autoregulation. As the brain has minimal tolerance for ischemic episodes, any decreases 
in cerebral circulation may have a profound effect (Sowers et al. 1995). 
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Locally, inflammation of endothelial cells lining cerebral vessels occurs because of 
microvascular occlusion due to embolic blockade or as a result of leukocyte-endothelial-platelet 
binding (del Zoppo, 1997).  Either way, there is a definitive interaction between inflammation, 
ischemia and the vascular endothelium. Leukocyte degranulation leads to free radical, hydrogen 
peroxide and proteolytic enzyme release further impairing vascular integrity (del Zoppo, 1997).  
Exposure of the blood to the CPB surface may amplify what would otherwise have been a 
harmless localized reaction. 
 
 
1.4 CPB and Diabetes 
Diabetes is a major risk factor for cardiovascular disease (Kannel et al. 1979). Diabetic 
patients are usually hypertensive and frequently have a history of myocardial infarction by the 
time they arrive in the operating room for CABG (Gravlee et al. 2008). Due to the nature of their 
disease, coronary vessel diameter is typically less than in non-diabetic patients (Cariou et al. 
2000). Preoperatively, diabetics have a greater likelihood of having triple vessel disease and a 
lower left ventricular ejection fraction (Jones et al. 1996). Diabetes mellitus is an independent 
risk factor for postoperative renal complications and this risk triples if renal function is already 
compromised preoperatively (creatinine > 140 µmol/l) (Mangano et al. 1998). Postoperative 
complications involving the kidneys have been linked to inflammation due to CPB, nephrotoxic 
medications, embolization, hemoglobinemia and inadequate renal perfusion (Mangano et al. 
1998).  
Post CABG risk of cognitive impairment in diabetics is significantly elevated compared to 
non-diabetics. Vigilant insulin treatment of hyperglycemia perioperatively appears to attenuate 
impairment (Kadoi et al. 2005). Prolonged periods of low venous O2 saturation during CPB, 
hypertension and high levels of HbA1c correlate with cognitive impairment (Kadoi et al. 2005).  
The risk of postoperative mediastinitis is 2-4% in diabetics compared to 1-2% in non-
diabetics, while mortality is tripled for diabetics should an infection of the mediastinum occur 
(Zerr et al. 1997). Tight glycemic control in diabetics postoperatively can reduce mediastinal 
infection risk to 1.5% (Furnary et al. 2003). Decreased endothelial cell proliferation equals 
decreased wound healing and increased endothelial cell expression of sVCAM-1 in diabetics in a 
hyperglycemic state (Birnbaum et al. 2006). 
Diabetics are known to be prothrombotic (Dalal et al. 2002). This translates into the potential 
of premature closure of surgical bypass grafts (Lytle et al. 1985). Diabetics are generally not 
given antifibrinolytics because the administration of these drugs can precipitate premature graft 
closure above and beyond the risk associated with the prothrombotic state of their disease. 
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The added postoperative risks to diabetics undergoing cardiac surgery and CPB suggest that 
BCC might be especially useful in attenuating the heightened inflammatory response 
experienced by these patients (Marcoux et al. 2009). 
 
 
1.5 CPB and Gender 
Females tend to be smaller and carry a lower circulating RBC volume compared to their male 
counterparts. Females therefore experience a slightly higher incidence of postoperative morbidity 
and mortality (Athanasiou et al. 2002; Puskas et al. 2008). The added perioperative risks to 
females undergoing CPB-assisted surgery suggest that BCC might be especially useful in 
decreasing morbidity and mortality in this high-risk group.  
 
1.6 BCC 
The ideal BCC should be as safe and functional as endothelial lining. The endothelial lining is 
difficult to reproduce however due to its complicated nature. Many biocompatible circuits have 
been used clinically worldwide throughout the years. Four of the BCC available in Canada were 
included in this study. After three decades of research, a non-reactive, non-thrombogenic BCC 
has yet to be manufactured. Nonetheless, in order for a BCC to be clinically practical, it must be 
durable, clinically and biologically inert, cost effective, easy to make and easy to sterilize. 
Additionally, there should be documented pre-market evidence describing an improvement in 
outcomes relative to uncoated circuits. 
Upon contact, plasma proteins are adsorbed onto the foreign extracorporeal surface 
completely covering the inner surface of the CPB circuit (Horbett, 1993). A subset of plasma 
proteins (mostly fibrinogen) is irreversibly bound to the circuit. Concentration of these proteins, 
once adsorbed to the CPB surface, is two to three times greater than what normally circulates 
throughout the vasculature (Horbett, 1993). Surface activity of the artificial surface will 
determine the composition of the bound monolayer of plasma proteins. Fibrinogen is selectively 
adsorbed and its concentration along with other plasma proteins adsorbed can change dependent 
upon many factors. These include duration of CPB, temperature, flow and hematological status 
of the patient, i.e., platelet count (Horbett, 1993). Though it is known that a hydrophilic artificial 
surface for blood contact is generally effective in decreasing platelet adhesion and thrombus 
formation (Kim, 1996) development of new biocompatible surfaces remains, by and large, by 
trial and error because of the lack of sufficient knowledge regarding blood response to artificial 
surfaces.  
The two methods developed to coat the inner surface of the BCC are surface bound heparin 
and surface-modifying additives. Commonly used for coating BCC, heparin can be bound to the 
PVC surface by either ionic or covalent bonding. Bonding of heparin molecules to the CPB 
component does not prevent it from having a bioactive surface (Wendel et al. 1999). Clinical 
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trials comparing the two types of heparin coatings had not proven the superiority of one type of 
bond over the other (Gorman et al. 1996; te Velthuis et al. 1997) until meta-analysis by 
Mahoney, (1998), which showed improved outcomes attained by covalently bonded heparin-
coated BCC. 
Heparin-bonded circuits have demonstrated variably attenuated complement activation 
(Lappegard, 2005), but without obvious improvement in clinical outcomes (Videm et al. 1999). 
Small concentrations of surface-modifying additives are added to the bulk biomaterial to reduce 
reactivity within their environment (Frechet, 1994). Synthetic polymers such as Trillium™ 
(Medtronic Inc.) (Baksaas et al. 1999), hyaluronan (Gunaydin, 2005), and poly-2-
methoxyethylacrylate (PMEA) (Terumo Med Inc.) (Ueyama, 2004) can be used to encapsulate 
and control reactive sites on the surface of the tubing (Frechet, 1994).  
In general, BCCs have demonstrated decreased fibrinogen deposition, decreased complement 
activation, decreased platelet activation and decreased inflammatory response compared to 
uncoated CPB circuits (Gunaydin, 2004; De Vroege et al. 2005; Zimmermann et al. 2007). A 
recent meta-analysis by Ranucci et al, (2009), unavailable when this study was conducted, 
concluded that patients undergoing CPB with a BCC had fewer RBC transfusions, lower rates of 
AF and spent a shorter time in intensive care unit (ICU) postoperatively. Seventy-eight percent 
of the BCC circuits included in their meta-analysis had heparin-based coatings, unlike our study 
where heparin and non-heparin based circuits were equally divided. Additionally some studies in 
the meta-analysis used full dose heparin in order to maintain activated clotting time (ACT) > 
480s whereas others relied on lower circulating heparin levels (ACT < 300s). All patients in the 
present study received full dose heparin necessary to maintain ACT > 480s equivalent to a 
heparin dose in the range of 400-500 units/kg.  
To date, duplicating the endothelial lining, and/or all properties therein, remains beyond 
reach. Genetic engineering is likely the only manner with which a true biomaterial could be 
manufactured (Edmunds, 1995). To date, this goal remains commercially and practically elusive. 
The present study compared four BCCs and their abilities to attenuate the inflammatory 
response and improve clinical outcomes. Furthermore, it also compared the effectiveness of 
circuit design, i.e., how effectively blood activation and hemolysis was minimized. Oxygenators 
have the greatest effect on the blood because they have the largest surface area within the CPB 
circuit. The surface area for blood: gas transfer of modern oxygenators designed to oxygenate 
and ventilate adults, ranges from 1.45-4.0 m2 (Gravlee et al. 2008). Coated oxygenators included 
in this study had surface areas ranging from 1.8-2.5 m2 where as the surface area for blood: gas 
transfer within the natural lungs is reported to be approximately 70 m2  (Hasleton, 1972). It is 
truly remarkable that the small surface area in commercial oxygenators can provide sufficient 
gas exchange capabilities to support an adult. One need only remember that patients undergoing 
CPB are anesthetized and cooled, and oxygen delivery can be anywhere from 21-100%.   
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Gas transfer is limited by the factors governed by the laws of diffusion. These include partial 
pressure differences driving the gases, surface area available for diffusion, thickness of the 
membrane and the amount of time the gas is in contact with a surface (dwell time). Solubility of 
the gas related to its molecular weight is also an important factor. Solubility need not be 
considered here however because oxygen, carbon dioxide and nitrogen are the only gases used 
consistently during CPB. Decreasing the distance gas needs to travel across artificial membranes, 
increasing the surface area for diffusion while minimizing priming volumes and increases in 
shear stress are all factors which come into play when oxygenator design is considered. These 
considerations are important because the greater the change in pressure (from high to low) when 
blood is in transit through the oxygenator (or any component of the CPB circuit), the greater the 
amount of blood damage (hemolysis and platelet activation) induced (Kawahito et al. 2001). 
Additionally most modern day oxygenators are coupled with a heat exchanger. Their efficiency 
at cooling and warming patients intraoperatively need also be considered.  
All oxygenators used in this study were made of porous, hollow, polypropylene fibers 
encapsulated in a polycarbonate shell. At the start of CPB, direct blood to gas contact occurs 
through these one-micron pores until a monolayer of plasma proteins is laid down. Poor 
oxygenator design and inadequate quality control has in the past lead to excessive platelet 
adhesion, high-pressures and oxygenator failure (Groom, 2002).  
 
1.6.1 Phosphorylcholine 
Phosphorylcholine-coated surfaces are coated with a derivative of the naturally occurring 
phosphatidylcholine (a constituent of the lipid bilayer of the cell membrane) (Whelan et al. 
2000). This BCC is designed to mimic the inert phospholipid nature of the endothelial wall 
(Gunaydin et al. 2004; Rubens, 2002).  
In an animal model, phosphorylcholine-coated stents implanted in the porcine coronary 
arteries did not produce an adverse inflammatory response throughout the study period of 12 
weeks post implantation (Whelan et al. 2000). Schulze et al. (2009) demonstrated improved 
platelet counts and reduced levels of TNF and IL-6 in their phosphorylcholine group when 
compared to an uncoated circuit group. Nevertheless, Draaisma et al. (2006) found no difference 
in clinical outcomes or complement activation when comparing 13 neonates and infants in a 
phosphorylcholine-coated group vs 15 infants in an uncoated group undergoing CPB-assisted 
cardiac surgical procedures. 
 
1.6.2 Bioline™  
Bioline™ (Maquet Dynamed Inc)-coated surfaces (used clinically since 1992) are composed 
of polypeptides and high molecular weight heparin (Wendel et al. 1999). The heparin molecules 
attached via ionic interactions and covalent bonds to polypeptides, are adsorbed onto the CPB 
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components (Wendel et al. 1999). The Bioline™-coating is similar in design to the Trillium™ 
coating (Jordan et al. 2007). A study by Seeburger et al. (2005) comparing Bioline™-coated 
circuits to Safeline (Maquet Dynamed Inc) recombinant albumin-coated circuits, demonstrated a 
greater increase in leukocyte gene expression in the Bioline™ circuits.  A study by Remadi et al. 
(2004), using a miniaturized Bioline™-coated circuit vs an uncoated control group, found 
decreased postoperative CRP levels and decreased troponin I levels in a group of adults 
undergoing aortic valve replacement. De Vroege et al. (2005) found decreased pulmonary 
dysfunction and decreased levels of C3b/c and elastase-alpha (1)-antitrypsin complex when 
comparing 26 Bioline™-coated circuits vs 25 uncoated circuits in patients undergoing CABG. 
Harig et al. (1999) found suppression of IL-6 combined with up-regulation of IL-10 in 
Bioline™-coated circuits when compared to an uncoated control group. 
 
1.6.3 PMEA 
Non-heparin-based PMEA has an exterior hydrophilic layer in contact with the blood and an 
inner hydrophobic polyethylene layer adherent to the CPB component. The hydrophilic water 
layer is designed to be nonreactive with similarly negatively charged cellular components in the 
blood. Contact activation is thus inhibited (Ikuta, 2004; Ueyama, 2004). A study by Suzuki et al. 
(2008) demonstrated decreased elevation of thrombin-antithrombin complex and neutrophil 
elastase levels in the PMEA coated group (n=6) when compared to a small uncoated group of 
pediatric patients (n=5) undergoing ventricular septal defect repair. In a larger study by Skrabal 
et al. (2006), 19 patients undergoing CPB-assisted cardiac surgical procedures were randomly 
assigned to the PMEA-coated group and 20 patients were assigned to an uncoated group. No 
significant difference was found in assayed inflammatory parameters between groups. An in 
vitro study comparing PMEA-coated oxygenators vs a heparin-coated and an uncoated 
oxygenator demonstrated similar attenuated increases of platelet activation in the PMEA and 
heparin-coated groups compared to control (Zimmermann, 2004). 
 
1.6.4 Trillium™  
Trillium™ surface-modifying additives (Medtronic Inc. Minneapolis, MN) are hydrophilic 
water-soluble synthetic polymers (plastic) bound to the components of the CPB circuit. 
Trillium™ coating is composed of sulphate/sulphonate groups, polyethylene chains and heparin 
(Gunaydin et al. 2004). Incorporating heparin as part of the coating is thought to partially inhibit 
activation of thrombin (Jordan et al. 2007). Polyethylene oxide is used as a spacer group. Its 
hydrophilicity and dynamic motion is thought to inhibit platelet interaction (Jordan et al. 2007).  
A clinical study by Baksaas et al. (1999) concluded that the Trillium™-coated CPB circuit 
caused less granulocyte and platelet activation as well as platelet loss compared to an uncoated 
circuit group. Tevaearai et al. (1999) compared a reduced heparin protocol (ACT= 180 sec) for 6 
hr of CPB in calves to full heparinization (ACT > 480 sec) with an uncoated circuit. The 
Trillium™-coated group (n = 3) had an attenuated fall in circulating platelets and lower plasma-
free hemoglobin levels. At the end of the procedure, there was significantly less fibrin clot found 
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in the dissected CPB circuit and fewer clot emboli found in the kidneys of the experimental 
animals upon autopsy. 
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2 OBJECTIVES 
 
2.1 Comparison of Clinical and Laboratory Outcomes Between Diabetics Treated with an 
Uncoated Circuit or a BCC  
Experiments and data analysis were conducted to assess whether diabetic patients who 
undergo CPB with a BCC have better outcomes than diabetic patients who undergo CPB with an 
uncoated circuit. 
 
2.2 Comparison of BCC Effect on Females 
Experiments and data analysis were conducted to assess whether female patients who undergo 
CPB with a BCC have better outcomes than female patients who undergo CPB with an uncoated 
circuit. 
 
2.3 Comparison of BCCs on the Release of SAMs 
Experiments were conducted to assess whether SAM analysis is consistent with published 
laboratory analysis to date. 
 
2.4 Comparison of BCC Effect in Attenuating Renal Dysfunction and Consequent Volume 
Retention  
Data analysis was conducted to assess whether patients who undergo CPB with a BCC have 
preserved renal function and diminished volume retention compared to patients who undergo 
CPB with an uncoated circuit. 
 
2.5 Comparison of BCC Effect on Bleeding and Transfusions 
Data analysis was conducted to assess whether patients who undergo CPB with a BCC have 
less bleeding postoperatively and fewer transfusions compared to patients who undergo CPB 
with an uncoated circuit. 
 
2.6 Comparison of BCC Effect on AF 
Data analysis was conducted to assess whether patients who undergo CPB with a BCC 
experience postoperative AF less frequently than patients who undergo CPB with an uncoated 
circuit. 
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2.7 Comparison of BCC Effect on Neurocognitive Outcome, and ICU and Hospital Length 
of Stay 
Experiments and data analysis were conducted to assess whether patients who undergo CPB 
with a BCC have preserved neurocognitive outcome, and decreased ICU and hospital length of 
stay compared to patients who undergo CPB with an uncoated circuit. 
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3 MATERIALS AND METHODS 
3.1. Materials 
3.1.1 Patient Population 
Ethics approval was obtained from the Biomedical Ethics Board of the University of 
Saskatchewan (EC # 2006-248) and the Saskatoon Health Region. Written informed consent was 
procured from all 101 consecutive patients undergoing coronary artery bypass grafting and/or 
valve surgery. Patients were enlisted into this prospective cohort study between July 2007 and 
April 2008. A preoperative antisaccadic eye movement test (ASEMT) was administered when 
patients were enlisted in the study. Each test was graded on 20 attempts only after the patient had 
clear understanding of the required visual response. A follow-up test was conducted on the 
morning of the 3rd postoperative day. This neurocognitive test is well described by Currie et al. 
(1991).  
The sample size of 101 patients was determined sufficient to detect an observed effect size of 
0.5 (medium effect) for statistical analysis using a one-tailed test with an observed power of 
0.802 (Soper, 2010).  
 
3.1.2 Exclusion Criteria  
SAMs are markers of inflammation and BCCs are designed to attenuate the inflammatory 
response. As a result, patients admitted as acutely emergent or afflicted with a chronic 
inflammatory disorder were excluded. Examples of these include: rheumatoid arthritis, systemic 
lupus erythematosus, Crohn’s disease, Wegener’s granulomatosis, sarcoidosis, osteoarthritis, 
debilitating chronic obstructive pulmonary disease, ulcerative colitis, psoriasis, and patients 
afflicted with multiple sclerosis. Patients who had suffered a recent stroke, seizures or afflicted 
with a neurodegenerative disease (Alzheimer’s or Parkinson’s) were also excluded.   
 
3.1.3 Anesthesia 
Upon entering the operating room, patients were pre-medicated with oxygen and 1-2 mg 
intra-venous of ativan. Intra-venous induction medications consisted of midazolam, sufentanil 
and propofol. Isoflurane and a sufentanil infusion were used for the maintenance of anesthesia 
while on bypass. Fifteen mL of whole blood was drawn from the arterial line and divided into a 
blood gas syringe, 3 vacuum tubes, ACT and heparin dose response cartridges. Heparin dose 
response cartridges were used to determine patient sensitivity to heparin and to calculate the pre-
bypass loading dose. Upon initiation of CPB, patients received the diuretic furosemide, the 
sedative midazolam and the muscle relaxant rocuronium. Before disconnection from CPB, 
patients received magnesium sulphate, calcium gluconate, dopamine and/or epinephrine.  
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3.1.4 CPB and Surgery 
All efforts were made in this study to have the shortest CPB circuits possible in order to 
minimize the inflammatory response to the artificial surface. Additionally differences in set up of 
all BCC circuits and the control group were minimized to allow for accurate circuit comparisons. 
The S3 or the S5 HLMs (Stockart, Germany) were used for all patients. All CPB circuits had 
open venous reservoirs and uncoated cardioplegia systems. Priming volume was consistent for 
the five CPB circuits and consisted of a combination of crystalloid and colloid; 50-300 mL 
normosol; 500 mL pentastarch 10%; 2.5 mL/kg of mannitol 20%; 50 mL of sodium bicarbonate 
and 10,000 IU of heparin. A pre-bypass filter effective to 0.2 µm was always used for priming of 
the CPB circuit. Every effort to minimize the use of cardiotomy suction was done. A cell saver 
was in use throughout the entire procedure minimizing shed blood return through the pump 
suckers back to the patient. The cell saver was used to remove and process shed blood from the 
wound before return to the patient. The volume of blood collected to the cell saver and returned 
to each patient was not significantly different between groups. 
CPB was initiated once the ACT reached 480 sec and the circulating heparin concentration 
within the patient reached 3mg/kg of body weight  (300 IU/kg). Patients were cooled to 32-33 ºC 
and supported using a non-pulsatile roller-pump. A cardiac index of 1.8-2.4 L/min/m2 was 
maintained. Patients were transfused if the hemoglobin level fell below 75-80 mg/L. All efforts 
were made to maintain mean arterial blood pressure within 60-80 mmHg. 
Shortly after initiation of CPB, a crossclamp was applied to the aorta and the heart was 
arrested with warm blood and KCl (20-30 meq/L). Cardioplegia was cooled upon cardiac 
quiescence and maintenance blood and KCL (5-10meq/L) was given intermittently. Once the 
coronary bypasses were completed and the valve(s) was repaired or replaced, de-airing and a 
final dose of warm KCL-free blood was given to the heart. Upon spontaneous return of the 
heart’s own cardiac rhythm and adequate systemic rewarming to 36.5 ºC the patient was weaned 
from CPB. 
Once all the cannulas were removed from the patient, a calculated protamine dose was given 
to reverse all circulating heparin. The remaining hemodiluted contents of the CPB circuit 
following CPB was processed by the cell saver and the resulting concentrated volume of RBC’s 
suspended in saline was infused into the patient. 
 
3.1.5 BCC 
3.1.5.1 Control 
The control circuit consisted of uncoated Dideco PVC tubing (Dideco, Mirandola, Modena, 
Italy), a Trillium™-coated Affinity oxygenator (Medtronic, Minneapolis, Minnesota), an 
uncoated 20 µm arterial line filter and an uncoated venous reservoir (Medtronic, Minneapolis, 
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Minnesota). The static priming volume of the Affinity oxygenator is 270 mL while the 
membrane surface area is 2.5 m2. 
 
3.1.5.2 Phosphorylcholine 
The Phosphorylcholine-coated BCC (Sorin/Dideco, Mirandola, Modena, Italy) consisted of 
Sorin/Dideco disposables, PVC tubing, a 20 µm arterial filter and a venous reservoir. The static 
priming volume of the Primox oxygenator is 250 mL while the membrane surface area is 1.87 
m2. 
 
3.1.5.3 Bioline™ 
The Bioline™-coated BCC (Maquet-Dynamed, Germany) consisted of Maquet-Dynamed 
disposables, PVC tubing, a 40 µm arterial filter (a 20 µm arterial filter was not available) and a 
venous reservoir. The static priming volume of the Quadrox oxygenator is 250 mL while the 
membrane surface area is 1.8 m2. 
 
3.1.5.4 PMEA 
The PMEA-coated BCC circuit (Terumo, NJ, USA) consisted of Terumo disposables, PVC 
tubing, a 20 µm arterial filter and a venous reservoir. The static priming volume of the Capiox 
RX25 oxygenator is 250 mL while the membrane surface area is 2.5 m2. 
 
3.1.5.5 Trillium™ 
The Trillium™-coated BCC consisted of Medtronic disposables, PVC tubing, a 20 µm arterial 
filter and a venous reservoir. The static priming volume of the Affinity oxygenator is 270 mL 
while the membrane surface area is 2.5 m2. 
 
3.1.6 Sample Collection  
Three blood samples were collected and transferred into vacutainer tubes at three selected 
intervals.  The first was a preoperative control sample taken in the operating room. The second 
sample was taken six hr postoperatively from the arterial line when the patient was in ICU. The 
final samples were collected via venipuncture on the ward 72 hr postoperatively. All samples 
were labeled, refrigerated at 4 ºC and left to clot until centrifugation within 4 hr. Samples were 
centrifuged at 3000 rotations per min for 15 min. Serum was then transferred into seven labeled, 
cryogenic, Eppendorf tubes and stored at -80 ºC until analysis. 
 
3.1.7 Demographics and Laboratory Data Acquisition 
Patient demographics are categorized and tabled according to circuit group.  The following 
data was included for comparison: weight; body mass index (BMI); age; smoking history; 
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preoperative medications and cardiac risk factors. Preoperative laboratory results were 
summarized. Parameters included for comparison were; white blood cell counts; serum urea and 
creatinine; baseline ASEMT results and percentage of patients with existing chronic AF per 
group. 
 
3.2. Methods 
3.2.1 Biochemical Analyses 
3.2.1.1 Enzyme-Linked Immunosorbent Assay (EIA) 
To evaluate inflammatory response, serum levels of the following SAMs sVCAM-1, sICAM-
1, sE-selectin and sL-selectin were quantified using commercial EIA kits (R&D Systems, 
Minneapolis, MN). All tests were run according to manufacturer’s instructions. Upper limit of 
normal for Quantikine human sVCAM-1, Quantikine human sICAM-1/CD54, human sE-
selectin/CD62E and human sL-selectin/CD62Ls was 200 ng/mL, 50 ng/mL, 8 ng/mL and 856 
ng/mL, respectively. Sensitivity for sVCAM-1, sICAM-1, sE-selectin and sL-selectin was 0.3 
ng/mL, 0.096 ng/mL, 0.009 ng/mL and 0.6 ng/mL, respectively. Coefficient of variance for intra-
assay and inter-assay precision for sVCAM-1, sICAM-1, sE-selectin and sL-selectin ranged 
between 5.0-8.8%, 5.0-6.8%, 6.6-8.7% and 3.6-7.8%, respectively.   
In order to attain a linear standard curve, each EIA kit required specific sample dilution. 
Testing started at full strength and ended at the following dilutions for each kit: sVCAM-1, 20-
fold; sICAM-1, 20-fold; sE-selectin, 10-fold; sL-selectin, 100-fold. 
The EIA Colormetric readings were done on a Biotek plate reader; model EL808 with 
standard filter wheels (405 nm, 450 nm, 490 nm, 630 nm). The spectrophotometer uses Biotek 
Gen5 Microplate Data Collection and Analysis software (Winooski, VT). 
 
3.2.1.2 Serum Glucose, Lactate, Urea and Creatinine 
Serum lactate levels were analyzed on a Radiometer Flex 815 analyzer (Radiometer, Canada). 
Glucose, urea and creatinine levels were determined on a Cobas 4000 series analyzer (Roche 
Diagnostics Canada, Laval, Quebec). Analytical detection limits of lactate, glucose, urea and 
creatinine values respectively are; 0.0-30 mmol/L; 0.0-41.6 mmol/L; 0.5-40 mmol/L and 5.0-
2700 µmol/L. Blood was collected via an arterial line and contained within BD Vacutainer tubes 
containing plasma separator lithium heparin until analysis. 
 
3.2.2 Statistical Analysis 
Descriptive statistics were run for all independent outcome variables. In order to better 
understand the data, initial observations included mean, standard deviation (SD), minimum 
result, maximum result and standard error. Upon presentation of results, only mean, standard 
deviation and P values are shown where applicable. One-way analysis of variance (ANOVA) for 
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all 101 patients in each group was undertaken to ensure comparability of base line demographic 
variables. One-way ANOVA’s were done to ascertain mean SAM differences between groups 
related to preoperative medications Aprotinin and Tranexamic Acid (TA), postoperative AF, 
permanent AF and smokers. As there were three categories for smoking (non, x-smoker, current 
smoker), ANOVA was rerun excluding x-smokers. The importance of gender and diabetes was 
ascertained using a one-way ANOVA. Chi-square was executed for categorical data. 
Correlations were run comparing all independent (circuit groups and demographics) and 
dependent outcome variables to ascertain and confirm existing relationships. Dependent group 
outcomes were compared using ANOVA and paired t-test comparisons. Paired two-tailed t-tests 
were performed to compare results of all laboratory parameters at the three different time 
intervals. A P value of less than 0.05 was considered significant. 
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4 RESULTS AND DISCUSSION 
4.1 Results, Patient Characteristics/Demographics 
Demographics were collected and compiled before surgery. Postoperative data collection 
continued until the patient was discharged from hospital. Demographics and clinical 
characteristics of the patients are summarized in Table 4.1. 
ANOVA was used to expose any differences between the groups. The five different groups 
were classified as independent variables or factors while the patient demographics were 
classified as the dependent variables when running the analysis. Other than antifibrinolytic 
administration, there were no significant differences. Further post-hoc analysis was not 
necessary. 
Aprotinin and TA, both antifibrinolytics, where unequally administered and dosage was not 
standardized according to patient weight.  The groups Bioline™ and PMEA did not receive 
Aprotinin as this drug was removed from market after the study began. Patients in the Bioline™ 
and PMEA BCC groups were therefore administered TA. Though they are not identical drugs, 
they were both given to achieve the same goal, which is to decrease postoperative hemorrhage. 
Patients with a history of diabetes did not receive antifibrinolytics. 
 
4.1.1 Diabetics  
To determine if there was enhanced SAM expression in diabetic patients, a one-way ANOVA 
was run using diabetic patients as the predictor.  The only SAM trending towards significance 
was sVCAM-1 at 6 hours (P = 0.067). Expression in the diabetic group was more elevated. 
Otherwise, there was no difference in SAM expression between diabetic and non-diabetic 
patients. 
Laboratory results were significantly elevated in diabetic patients compared to non-diabetics 
for serum creatinine at baseline (P = 0.013), serum creatinine at six hr (P = 0.019), serum 
creatinine at 72 hr (P = 0.001), baseline serum urea (P < 0.001) and serum urea at 72 hr (P = 
0.011) as is demonstrated in Table 4.2. Scrutiny of the phosphorylcholine BCC group in which 
there were 8 diabetic and 12 non-diabetic patients revealed significantly elevated preoperative 
serum creatinine levels in the diabetic patients. Serum creatinine levels remained significantly 
elevated at the 72nd postoperative hr. Significantly different laboratory results in all groups did 
not translate into worse postoperative outcomes in regards to ICU or hospital length of stay. 
Neurologic outcomes were similar between diabetics and non-diabetics as well. Comparison 
between the diabetic patients treated with a BCC and diabetic patients treated with the control 
circuit yielded several interesting findings despite the fact that the analysis was not sufficiently 
powered. Results in Table 4.3 show decreased transfusions of RBCs and platelets, coupled with a 
decrease in postoperative chest tube drainage (CTD) in the BCC group. 
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Table 4.1 Study patient demographics and baseline preoperative conditions 
 Control 
N = 18 
Phosph 
N = 20 
Bioline™ 
N = 21 
PMEA 
N = 21 
Trillium™ 
N = 21 
P value   
Sex  
(% Female) 
50 20 24 24 19 0.185   
Diabetics 
(%) 
17 40 29 10 24 0.201   
Age  
(years) 
67±  
9.6 
68 ± 
 9.2 
67 ± 
 12.4 
67± 
 8.9 
69 ±  
9.7 
0.966   
Smoke  
(%) 
5 20 22 10 10 0.357   
Weight  83± 
16.8 
88 ± 
15.4 
82 ± 
 16.5 
88 ± 
 11.3 
86 ±  
9.4 
0.569   
BMI  30± 
5.2 
30 ± 
 4.5 
 28 ±  
4.7 
30± 
 4.4 
30 ±  
5.0 
0.945   
Aprotinin 
(%) 
28 25 0 0 38 0.001   
TA (%) 33 25 29 38 19 0.714   
WBC x109/L 6.8± 
1.4 
7.1± 
1.5 
6.6 ±  
1.9 
7.0± 
2.4 
6.6 ±  
1.8 
0.857   
Chronic AF 
(%) 
0 20 10 10 10 0.380   
Serum 
Creatinine  
97± 
17.3 
102 ± 
23 
94 ± 
 16.1 
92 ± 
 13.8 
100 ±  
23 
0.463   
Serum Urea  5.8± 
1.8 
5.4 ± 
1.9 
5.5 ±  
1.6 
5.0± 
1.2 
6.1 ±  
2.5 
0.354   
ASEMT-1 
(%) 
88 94 92 95 94 0.185   
Mean ± SD where applicable. Phosph phosphorylcholine; Weight kg; BMI body mass index; 
WBC, white blood cell count; TA Tranexamic Acid; Creatinine µmol/L; Urea mmol/L; ASEMT-
1, antisaccadic eye movement test refers to preoperative cognitive neurological assessment 
scores 
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Table 4.2 Study outcome differences between diabetics and non-diabetics  
 Diabetics Non-Diabetics P value 
Females (N) 18 9 0.172 
Males (N) 15  59 0.172 
RBC (units) 1.71 ± 2.01 0.79 ± 1.3 0.045 
Baseline 
Serum 
Creatinine 
105.54 ± 28.15 94.51 ± 14.59 0.013 
6 hr 
Serum 
Creatinine 
111.21 ± 28.88 98.82 ± 19.69 0.019 
72 hr   
Serum 
Creatinine 
115.67 ± 32.29 98.18 ± 18.08 0.001  
Baseline 
Urea 
6.80 ± 2.58 5.18 ± 1.48 0.000 
72 hr Urea 7.27 ± 3.74 5.57 ± 2.28 0.011 
Mean ± SD; Creatinine µmol/L; Urea, mmol/L  
 
Table 4.3 Significant diabetic outcome differences between treatment groups 
 BCC group 
N = 21 
Control Group 
N = 3 
P Value 
RBC (units) 1.38 ± 1.94 4.0 ± 0.00 0.031 
Platelets (units) 0.48 ± 1.50 5.0 ± 8.66 0.022 
CTD (mL) 748.81 ± 396.83 1551.67 ± 1611.48 0.046 
Ventilation (hr) 8.57 ± 4.01 14.00 ± 6.23 0.053 
 
Mean ± SD  
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4.1.2 Sex-Based Variations  
When all 101 patients were evaluated for sex-based outcome variations, several significant 
differences were found as shown in Table 4.4. In comparison to their male counterparts, females 
were transfused more units of RBC (P = 0.009), had a higher postoperative glucose (P = 0.014), 
a lower serum creatinine at 6 hr (P = 0.011), a lower urea at 6 hr (P = 0.044), spent more time on 
a ventilator (P < 0.001) and more time in ICU (P = 0.022). In order to ascertain the importance 
of the identical number of females in the control group (females = 9, males = 9), one-way 
ANOVA using sex as the predictor was conducted looking at all postoperative outcomes. A 
lower preoperative baseline serum creatinine was the only significantly different sex-based 
observation in the control group. When the females in the control group were compared to the 
females in the BCC group, L-selectin at 6 hr was lower in the BCC group (P = 0.020) 
demonstrating decreased activation of WBC. Importantly, females in the BCC group also 
received fewer platelet transfusions (p = 0.039). 
 
Table 4.4 Study outcome differences between genders 
Variable Male (n=74) Female (n=27) P value 
BMI 29.32 31.7 0.023 
RBC (units) 0.77 ± 1.44 1.67 ± 1.67 0.009 
6 hr Glucose  8.98 ± 2.15 10.23 ± 2.56 0.014 
6 hr Creatinine 105.22 ± 21.84 92.30 ± 22.65 0.011 
6 hr Urea 5.82 ± 1.75 5.00 ± 1.88 0.044 
Ventilation 
Time (hr) 
7.56 ± 3.4 14.44 ± 13.39 0.000 
ICU 
Time (hr) 
23.69 ± 4.54 28.70 ± 17.03 0.022 
 Mean ± SD; Creatinine µmol/L; Urea µmol/L; Glucose mmol/L 
 
4.2 CPB Data and Postoperative Resource Utilization Categorized by Group  
Patient CPB data and postoperative results categorized by BCC groups are shown in Table 
4.5. One-way ANOVA was used to expose any differences between groups. The five different 
groups were classified as independent variables or factors, while CPB data and resource 
utilization were classified as dependent variables when running analysis. No significant 
differences were found. Of note, three of the five groups (control, Phosph and Trillium) were 
administered the antifibrinolytic aprotinin. Two of the three groups receiving aprotinin showed 
significantly reduced CTD postoperatively; (P = 0.03) for the phosphorylcholine group and (P = 
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0.043) for the Trillium™ group, respectively. All groups including Bioline and PMEA received 
TA. TA was not as effective at decreasing postoperative hemorrhage.  
 
Table 4.5 CPB data and postoperative resource utilization categorized by group 
N  
Control 
18 
Phosph 
20 
Bioline™ 
21 
PMEA 
21 
Trillium™ 
21 
P value 
Bypass  
(min) 
100 ± 
 21.2 
100 ± 
20.1 
110 ± 
 20.8 
101 ± 
 25.9 
97 ±  
21.7 
0.413 
Crossclamp 
(min) 
80 ± 
 19.1 
79 ±  
18.5 
88 ±  
19.9 
82 ±  
22.9 
77 ±  
18.8 
0.449 
Surgery 
(% CABG) 
67% 70% 81% 86% 76% 0.539 
CTD 
(mL) 
789 ± 
 733 
756 ± 
  464 
848 ± 
 430 
1004 ± 
 729 
899 ± 
 627 
0.718 
RBC (units) 1.4 ±  
1.7 
0.8 ±  
1.5 
1.3 ±  
1.7 
0.7 ±  
1.2 
1.0 ±  
1.6 
0.535 
FFP (units) 0.1 ±  
0.5 
0.3 ±  
1.3 
0.29 ± 
 0.96 
0 0 0.550 
Platelets 
(units) 
1.4 ±  
3.8 
1.0 ±  
2.1 
0.71 ± 
 1.8 
0.24 ± 
 1.1 
1.0 ±  
2.6 
0.643 
Ventilation 
Time (hr) 
10.4 ± 
4.9 
8.1 ±  
4.1 
8.6 ±  
3.7 
12.7 ± 
 15.7 
7.2 ±  
2.8 
0.198 
ICU Time 
(hr) 
24.9 ± 
 6.6 
23.7 ± 
4.7 
24.7 ± 
 6.3 
28.8 ± 
 18.5 
23.0 ± 
 3.8 
0.365 
Hospital 
Length of Stay 
(days) 
5.6 ±  
2.1 
5.9 ±  
3.9 
5.9 ±  
3.2 
5.9 ±  
1.9 
5.1 ±  
1.1 
0.875 
Pump balance 
(mL) 
784 ± 
 782 
432 ± 
 466 
719 ± 
 497 
454 ± 
 485 
765 ± 
 989 
0.267 
Mean ± SD where applicable. Phosph phosphorylcholine; CTD Chest tube drainage, cumulative 
to 18 hr. Test for homogeneity of variance significant (P < 0.05) for UFFP and UPlatelets  
 
 
 
 
 
 
 
 
 
 
 
38 
4.3 CPB and SAM 
Table 4.6 shows mean serum SAM results and SD. All but sE-selectin baseline compared to 6 
hr postoperatively showed significant changes in a two-paired sample t-test of SAM levels.   
Table 4.6 Serum SAM values in ng/mL  
N = 101 Baseline 
Pre-op  
6 hr post-op 
 
72 hr post-op 
sVCAM-1 721 ± 308 799 ± 356** 1036 ± 377††§§ 
sICAM-1  251 ± 76 226 ± 78** 308 ± 120 ††§§ 
sE-selectin  37 ± 14 39 ± 16 34 ± 14     ††§§ 
sL-selectin  668 ± 223 507 ± 187** 547 ± 199 ††§ 
Mean ± SD 
** 6 hr compared to baseline (P < 0.01);  
††  72 hr compared to baseline (P < 0.01);  
§ 72 hr compared to 6 hr (P < 0.05); 
§§  72 hr compared to 6 hr (P < 0.01). 
Significantly elevated levels of sVCAM-1 (P = 0.013) were found at baseline in patients who 
went on to develop AF postoperatively. These levels were still significantly elevated at 6 (P = 
0.033) and 72 hr (P = 0.002). sVCAM-1 expression in patients with AF is demonstrated in Table 
4.7. One patient with AF had exceptionally high sVCAM-1 levels at all time intervals and was 
removed from the analysis as an outlier.  
 
Table 4.7 sVCAM-1 expression in patients with postoperative AF 
N = 100 AF 
N = 32 
No AF 
N = 68 
P Value 
Baseline 
sVCAM-1 
784 ± 261 661 ± 207 0.013 
6 hr sVCAM-1 845 ± 303 718 ± 255 0.033 
72 hr sVCAM-1 1116 ± 319 919 ± 256 0.002 
Mean ± SD in ng/mL; AF atrial fibrillation; No AF no atrial fibrillation 
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4.4 Mean Serum SAM Levels in all Groups 
4.4.1 sVCAM-1 Expression 
sVCAM-1 expression is shown in Table 4.8. Serum levels rose in all groups from baseline 
through to 72 hr with a significant change from baseline to 72 hr and from 6 hr to 72 hr in all 
groups.  
 
There was no significant difference in sVCAM-1 expression identified between groups either 
at baseline or at 6 and 72 hr. When the control group was compared to all the patients in the BCC 
group, no difference in sVCAM expression was found. 
 
Table 4.8 Serum sVCAM-1 concentrations 
sVCAM-1 Control 
N = 18 
Phosph 
N = 20 
Bioline™ 
N = 21 
PMEA 
N = 21 
Trillium™ 
N = 21 
Pre-op 
baseline 
697 ± 214 822 ± 506 654 ± 216 673 ± 239 760 ± 260 
6 hr 785 ± 321 949 ± 525 727 ± 274 731 ± 281 809 ± 314 
72 hr 1035 ± 335††§§ 1177 ± 548†† 906 ± 282††§§ 988 ± 312††§§ 1079 ± 334††§§ 
Mean group results in ng/mL ± SD; Phosph phosphorylcholine 
†† 72 hr compared to pre-op (P < 0.01);  
§ 72 hr compared to 6 hr (P < 0.05);  
§§ 72 hr compared to 6 hr (P < 0.01). 
 
 
4.4.2 sICAM-1 Expression 
sICAM expression is shown in Table 4.9. Significant differences were observed in all groups 
between baseline and 72 hr, and between 6 hr and 72 hr. All sICAM values decreased at 6 hr 
from baseline, whereas values at 72 hr were significantly higher than that at baseline. A 
significant difference in sICAM expression between baseline and 6 hr was found in the uncoated 
control group alone.  
 
There was no significant difference in sICAM expression identified between BCC groups.  
When all patients in the BCC group were compared to the control group in an independent 
samples t-test however, it was found that sICAM decreased by a greater amount (P = 0.001) at 6 
hr in the control group compared to the BCC study group. 
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Table 4.9 Serum sICAM-1 concentrations 
sICAM Control 
N = 18 
Phosph 
N = 20 
Bioline™ 
N = 21 
PMEA 
N = 21 
Trillium™ 
N = 21 
Pre-op 
baseline 
231 ± 87 247 ± 84 272 ± 68 270 ± 62 232 ± 72 
6 hr 200 ± 75* 227 ± 62    243 ± 71  231 ± 103  224 ± 75    
72 hr 297 ± 153 †§§ 284 ± 110 †† §§ 326 ± 120 §§ 328 ± 93 ††§§   302 ± 130 †§§ 
Mean group results in ng/mL ± SD; Phosph phosphorylcholine;  
*  6 hr compared to pre-op baseline (P < 0.05);  
† 72 hr compared to pre-op baseline  (P < 0.05);  
††  72 hr compared to pre-op baseline  (P < 0.01);  
§§  72 hr compared to 6 hr (P < 0.01) 
 
4.4.3 sE-selectin Expression 
sE-selectin expression is shown in Table 4.10. Very little difference in sE-selectin expression 
was found between any time periods other than in Trillium and PMEA. The Trillium group 
showed a significant change in sE-selectin expression between 6 and 72 hr, and between baseline 
and 72 hr. A significantly lower value was observed in the PMEA group from baseline to 72 hr. 
No significant difference was found between control and BCC groups.  
 
 
Table 4.10 Serum sE-selectin concentrations 
sE-selectin Control 
N = 18 
Phosph 
N = 20 
Bioline™ 
N = 21 
PMEA 
N = 21 
Trillium™ 
N = 21 
Pre-op baseline 40 ± 13 33 ± 13 40 ± 15 38 ± 17 33 ± 12 
 
6 hr 40 ± 15 38 ± 19 43 ± 15 37 ± 17 35 ± 14 
 
72 hr 39 ± 14 31 ± 13 
 
39 ± 12 34 ± 16† 29 ± 12††§§ 
Mean group results in ng/mL ± SD; Phosph phosphorylcholine  
†  72 hr compared to pre-op baseline  (P < 0.05);  
†† 72 hr compared to pre-op baseline  (P < 0.01);  
§§  72 hr compared to 6 hr (P < 0.01) 
 
4.4.4 sL-selectin Expression 
sL-selectin results are shown in Table 4.11. Change in serum levels from baseline to 6 hr was 
significant for phosphorylcholine, Bioline™, Trillium™ and PMEA. This change was not 
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significant for the control group. Change in expression was significant from 6 hr to 72 hr in the 
phosphorylcholine and Bioline™ groups. Change in expression was significant in all groups 
from baseline to 72 hr.  
 
sL-selectin levels were significantly elevated in the Control group when compared to 
Bioline™ (P < 0.007) and Trillium™ (P < 0.039) at 6 hr postoperatively. No significant 
differences between the groups remained at 72nd hr. When the BCC patients were grouped 
together and compared to the patients in the control group it was found that sL-selectin 
expression was significantly higher (P = 0.005) in the control group at 6 hr. This difference no 
longer existed at 72 hr. 
 
Table 4.11 Serum sL-selectin concentrations  
sL-selectin Control 
N = 18 
Phosph 
N = 20 
Bioline™ 
N = 21 
PMEA 
N = 21 
Trillium™ 
N = 21 
Pre-op 
baseline 
736 ± 229 751 ± 340 
 
604 ± 170 
 
666 ± 157 594 ± 136 
6 hr 635 ± 194# 
 
528 ± 255** 437 ± 137**# 486 ± 122** 471 ± 159**# 
72 hr 617 ± 161†† 620 ± 303†† § 507 ± 183†§ 520 ± 155†† 594 ± 125†† 
Mean group results in ng/mL ± SD; Phosph phosphorylcholine  
**  6 hr compared to pre-op baseline  (P < 0.01)  
†  72 hr compared to pre-op baseline  (P < 0.05)  
††  72 hr compared to pre-op baseline  (P < 0.01)  
§ 72 hr compared to 6 hr (P < 0.05)  
#  Difference between control and Bioline™ (P = 0.007) and control and Trillium™ (P = 
0.039) 
 
 
4.5 Effect of BCC on Common Clinical Parameters 
4.5.1 Changes from Baseline to 72 hr in Serum Creatinine, Urea, Lactate and Glucose 
Measured serum creatinine and urea levels along with postoperative serum lactate and glucose 
results are shown in Table 4.12. Phosphorylcholine group alone exhibited a significant change in 
mean serum creatinine levels between baseline and 6 hr. This group also demonstrated a 
significant change from 6 to 72 hr unlike any other group. Measured serum creatinine levels 
from baseline to 72 hr were significantly different in the two heparin-coated BCC groups 
Bioline™ and Trillium™.  
 
Serum urea values were significantly different from baseline to 6 hr and from baseline to 72 
hr in the phosphorylcholine and Bioline™ BCC groups.  
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Trillium™ urea levels at 6 hr postoperatively were significantly higher than Bioline™ (P = 
0.044) and PMEA (P = 0.021) with continuing significance between Trillium™ and PMEA (P = 
0.038) at 72 hr. Glucose and lactate levels were not different between groups. 
 
 
Table 4.12 Effect of BCC on chemistry and renal function parameters 
Variable Control Phosph Bioline™ PMEA Trillium™ 
N 18 20 21 21 21 
Pre serum 
 creatinine  
97 ± 17 102 ± 23 94 ± 16 92 ± 14 100 ± 23 
6 hr serum 
 creatinine  
104 ± 27 111 ± 27* 96 ± 23 96 ± 14 102 ± 21 
72 hr serum  
creatinine  
103 ± 21 106 ± 23§ 103 ± 22† 92 ± 14 109 ± 31† 
Pre urea  5.8 ± 1.8 5.4 ±1.9 5.5 ± 1.6 5.0 ± 1.2 6.1 ± 2.5 
6 hr urea  5.6 ± 1.6 6.0 ± 1.9** 5.0 ± 1.7**# 4.9 ± 1.4# 6.5 ± 2.0# 
72 hr urea  6.0 ± 2.9 6.9 ± 2.9† 5.6 ± 2.1† 4.6 ± 1.4# 7.0 ± 3.7# 
6 hr serum 
 lactate  
1.9 ± 0.9 1.8 ± 0.9 1.7 ± 0.88 2.0 ± 1.0 1.9 ± 1.2 
6 hr 
 glucose  
10.1 ± 1.7 8.6 ± 2.3 8.5 ± 2.4 10.4 ± 2.6 9.0 ± 1.9 
Mean group results ± SD where applicable. Phosph phosphorylcholine; Creatinine µmol/L, urea 
mmol/L, lactate mmol/L, glucose mmol/L 
*  6 hr compared to pre-op baseline   (P < 0.05); 
**   72 hr compared to pre-op baseline   (P < 0.01);  
†   72 hr compared to pre-op baseline   (P < 0.05);  
§  72 hr compared to 6 hr (P < 0.05);  
#   Group differences (P < 0.05) 
 
4.5.2 Bleeding and Transfusion Requirements 
Table 4.13 shows postoperative bleeding and transfusion requirements. This was the blood 
lost through chest tubes, measured at 18 hr, and units of blood products transfused until hospital 
discharge. These differences were not statistically different between groups nor were they 
different when all the BCC groups were compared to the control group. 
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Table 4.13 Bleeding and transfusion requirements 
 Control Phosph Bioline™ PMEA Trillium™ P value 
N 18 20 21 21 21 ------ 
CTD 
(mL) 
789 ± 
 733 
756 ±  
464 
848 ±  
430 
1004 ±  
729 
899 ±  
627 
0.718 
RBC 
(units) 
1.4 ±  
1.7 
0.8 ±  
1.5 
1.3 ±  
1.7 
0.7 ±  
1.2 
1.0 ±  
1.6 
0.535 
FFP 
(units) 
0.1 ±  
0.5 
0.3 ±  
1.3 
0.29 ± 
 0.96 
0 0 0.550 
Platelets 
(units) 
1.4 ±  
3.8 
1.0 ±  
2.1 
0.71 ±  
1.8 
0.24 ± 
 1.1 
1.0 ±  
2.6 
0.643 
Mean ± SD where applicable. Phosph phosphorylcholine; CTD Chest tube drainage, cumulative 
to 18 hr; RBC units of RBC transfused; FFP units of FFP transfused; Platelets units of platelets 
transfused. Test for homogeneity of variance significant (P < 0.05) for FFP and Platelets  
 
4.5.3 Effect of BCC on AF, Changes in Weight, Pump Balances and WBC Counts 
 
WBC counts were significantly different between all time periods for each group except 
Bioline™ from 6 hr to 72 hr as shown in Table 4.14. Table 4.14 also shows the significantly 
different weight changes from baseline to 6 and 72 hr. There were no significant differences in 
mean pump balances between groups.  
 
Despite what appears to be a large increase in new incidences of AF in the PMEA BCC group 
(8 new patients), this was not significant (P = 0.24).  
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Table 4.14 Patient changes in WBC count, weight, pump balance and incidence of AF  
 Control Phosph Bioline™ PMEA Trillium™ 
 N = 18 N = 20 N = 21 N = 21 N = 21 
Pre WBC 6.8 ±  
1.4 
7.1 ±  
1.5 
6.6 ±  
1.9 
7.0 ±  
2.4 
6.6 ±  
1.8 
6 hr WBC  14.5 ± 
 3.9**  
15.5 ±  
3.4** 
12.2 ± 
 4.4** 
15.5 ± 
 6.8** 
15.9 ± 
 6.0** 
72 hr WBC                      11.6 ± 
 2.9††§§  
12.5 ±  
3.4††§§ 
11.2 ±  
2.8†† 
12.4 ± 
 5.1††§§ 
12.1 ± 
 3.7††§§ 
Pre Weight  82.9 ±  
16.8 
88.0 ±  
15.4 
82.4 ±  
17.2 
88.3 ±  
11.3 
85.8 ±  
9.4 
6 hr Weight 85.2  ± 
 16.4** 
91.3 ± 
14.7** 
85.9 ± 
 17.2** 
92.7 ± 
 11.0** 
88.2 ± 
10.2** 
72 hr 
 Weight 
83.0  ± 
 15.9†§§ 
90.6 ±  
15.5†† 
84.2 ± 
17.1††§§ 
90.0 ± 
 11.1§§ 
87.4 ± 
 10.0††§§ 
Pump 
balance 
(mL) 
784 ± 
782 
432 ±  
466 
719 ±  
497 
454 ±  
485 
765 ±  
989 
AF Chronic 
N (%)  
0 (0) 4 (20) 2 (10) 2 (10) 2 (10) 
AF Postop  
N (%)  
3 (17) 3 (19) 3 (24) 8 (42) 6 (32) 
AF Discharge  
N (%) 
0 (0) 1 (6) 0 (0) 2 (11) 0 (0) 
Mean group results ± SD where applicable; Phosph phosphorylcholine; WBC white blood cells x 
10 9 /L; Weight kg; AF atrial fibrillation; N number of patients 
**  6 hr compared to pre (P<0.01)  
†  72 hr compared to pre (P<0.05)  
††  72 hr compared to pre (P<0.01)  
§§ 72 hr compared to 6 hr (P<0.01)  
 
4.5.4 Neurocognitive Outcomes and Intensive Care and Hospital Length of Stay  
Mean group results of the antisaccadic eye movement test, which were done preoperatively 
and at 72 hr postoperatively, are shown in Table 4.15. One-way ANOVA was used to expose 
possible differences between groups. When running statistical analyses, the five groups were 
classified as independent variables or factors while ventilation, ICU time and hospital length of 
stay were classified as dependent variables. No significant differences were found. Paired 
samples t-tests were run for assessment of the ASEMT. Significant differences from baseline 
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values were seen for PMEA and Trillium™ groups. Total time requiring mechanical ventilation 
and intensive care, as well as total time spent in hospital was not significantly different between 
groups. 
 
Table 4.15 Patient neurocognitive outcomes, ventilator times, and ICU and hospital length of 
stay 
Group Control 
N = 18 
Phosph 
N = 20 
Bioline™ 
N = 21 
PMEA 
N = 21 
Trillium™ 
N = 21 
P value 
0.185 Pre-op 
ASEMT 
(%) 
88 94 92 94 94 
 
72 hr 
ASEMT 
(%) 
93 
 
 
86 
 
 
85 
 
 
81 
 
 (P = 0.029) 
87 
 
 (P = 0.023) 
 
Ventilation 
Time (hr) 
10.4 ± 4.9 
 
8.1 ± 4.1 
 
8.6 ± 3.7 
 
12.7 ± 15.7 
 
 
7.2 ± 2.8 
 
 
0.198 
ICU Time 
(hr) 
24.9 ± 6.6 
 
23.7 ± 4.7 24.7 ± 6.3 
 
28.8 ± 18.5 
 
23.0 ± 3.8 
 
0.365 
Hospital 
Length of 
 Stay (days) 
5.6 ± 2.1 5.9 ± 3.9 5.9 ± 3.2 5.9 ± 1.9 5.1 ± 1.1 0.875 
Mean ± SD; Phosph phosphorylcholine; ASEMT antisaccadic eye movement test; Phosph 
phosphorylcholine 
 
4.6 Discussion 
4.6.1 Comparison of BCC Effect on Diabetic Patients  
Diabetic patients are susceptible to premature graft closure and renal failure due to the nature 
of their disease. Antifibrinolytic administration was withheld in these patients because of the 
potential drug-induced amplification of these risks. As the diabetic patients in this study were not 
administered antifibrinolytics, a relevant comparison of postoperative bleeding and transfusion 
requirements was possible. Diabetics who underwent CPB with a BCC did bleed less and did 
receive fewer RBC transfusions perioperatively. Unfortunately, as there were only 3 diabetic 
patients in the control group vs 21 diabetic patients in the BCC group, the results from these 
analyses cannot be considered conclusive because of insufficient power. This comparison in a 
well-designed study merits future consideration. 
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Markers of inflammation were higher in diabetics preoperatively as demonstrated by 
increased sVCAM-1 serum levels. Postoperatively, WBC counts were elevated and serum urea 
and creatinine levels were significantly higher than in non-diabetics. At best, one would hope to 
see no difference in the above stated laboratory results between diabetics and non-diabetic when 
a BCC is used. This was not the case. ICU and hospital length of stay was not significantly 
different between any of the groups observed or between the BCC groups and the uncoated 
control group. Scrutiny of the phosphorylcholine BCC group consisting of eight diabetics and 12 
non-diabetics failed to demonstrate important clinical outcome differences. This may have been 
due to a type II error. Larger study groups may have unmasked important clinical outcome 
differences as opposed to our observations in a smaller group. The diabetic patients in the BCC 
groups did not have better outcomes than the diabetic patients in the control group. BCCs may 
not be effective enough in diminishing inflammatory response to the point of improving 
important clinical outcomes such as ICU and hospital length of stay, both of which are 
influenced by a multitude of critical factors beyond coated CPB circuits.  
 
4.6.2 Comparison of BCC Effect on Females 
When all 101 patients were included for comparison, our observations yielded the expected 
sex-based outcome differences, based upon reported studies. The CPB circuit impacted more 
significantly on females, resulting in higher tranfusion requirements and lower serum creatinine 
and urea levels, all of which are subsequent to hemodilution incurred during CPB. The mean 
BMI of the 27 females included in this study was higher than for the 74 males, vividly 
demonstrating how susceptible females are to the hemodilution effect of CPB. Lower circulating 
RBC volumes (relative to increased hemoglobin levels in males) predisposes females to 
hemodilution, transfusions, respiratory problems, and mediastinal infections (Ranucci M, et al. 
2008). Females in our study did indeed spend significantly more time on a mechanical ventilator 
and in ICU as compared to males. Higher postoperative glucose levels could be the result of an 
elevated inflammatory response in females when compared to males. A type II error was likely 
the reason why no sex-based outcome differences were observed when the 9 females were 
compared to the 9 males in the control group.  
Females in the BCC groups had improvements in outcomes when compared to the females in 
the control group. The decreased inflammatory response observed, though short lived, was 
enough to decrease the need for platelet transfusions. Clinical protocols resulting in decreased 
transfusion requirements should be adopted as standard of practice. The role of the BCC in 
improving the remaining laboratory and clinical outcomes in females was however limited. 
Further improvements will likely only be achieved from a multi-factorial effort at diminishing 
the preoperative anemia associated with females coupled with a smaller CPB circuit. 
 
 
 
 
 
 
 
 
47 
4.6.3 SAM Expression due to CPB 
Results from this study showed that SAM expression changed significantly from baseline to 
seventy-two hr in all 5 groups except for sE-selectin. Wildhirt et al. (2001) and Serrano et al. 
(2010) noted similar significant increases in sICAM expression in their on-pump group from 
baseline to seventy-two hr compared to their off-pump group in their study. Higher on-pump 
postoperative sICAM levels did not result in worse clinical outcomes for the patients in those 
studies.  The results of Wei et al. (2003) show the same immediate postoperative fall in sICAM 
levels after on-pump procedures as seen in our study whereas the immediate postoperative 
sICAM level in off-pump cardiac procedures remained near baseline levels. In both groups 
sICAM levels had risen in a similar fashion at seventy-two hr to what was observed in our study. 
Patients who undergo CPB can expect to gain anywhere from 2-4 kg during the perioperative 
period. This increased weight is due to the added fluid volume from CPB induced hemodilution 
and the necessary volume requirements due to interstitial fluid shifts (third spacing). Greater cell 
membrane permeability is consequent to the inflammatory response. Consequently, it would 
seem that the decreased sICAM levels seen at 6 hr are sensitive to CPB induced hemodilution. 
Mobilization of this fluid via diuresis in the postoperative period generally returns the patient to 
their preoperative weight. There was nothing found in the literature to explain why sICAM was 
sensitive to hemodilution while sVCAM was not. Importantly, results from Kalawski et al. 
(2003) compared sVCAM and sICAM analysis from blood sampled from an arterial line vs 
blood sampled from the coronary sinus upon reperfusion in patients undergoing CABG. The aim 
of their study was to assess the effectiveness of cold blood over cold crystalloid cardioplegia in 
terms of myocardial protection. Measured sICAM levels were elevated 30 min post-reperfusion 
when measured from the coronary sinus but decreased when the samples were drawn from the 
arterial line. Further evidence that sICAM is susceptible to hemodilution. sVCAM levels did not 
differ based on the sampling site. When sampled from the coronary sinus, sICAM and sVCAM 
increased more significantly in the cold crystalloid group after myocardial reperfusion 
demonstrating unsurprisingly improved myocardial protection when using whole blood. As the 
significant drop in sICAM levels in this study was evident in the un-coated control group alone, 
one could conclude that the BCC were able to attenuate the initial inflammatory response as 
evidenced by higher 6 hr BCC sICAM levels.  
Postoperative sVCAM-1 (Wan et al. 2004) and sE-selectin (Matata et al. 2000) levels were 
higher in the on-pump group when compared to off-pump cardiac surgery as well. No 
postoperative clinical outcome differences between the on and off-pump groups in these studies 
were observed despite these higher SAM levels. Hambsch et al. (2002) stated that sL-selectin 
levels, similarly significantly reduced postoperatively in the on-pump group compared to our 
study, were the result of circulating neutrophils post-CPB having significantly reduced 
adhesiveness and activity. This phenomenon also appears to be sustained for greater periods of 
time (as much as three days) in the on-pump group when compared to their control group of off-
pump patients.  
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Patient response to surgery and CPB was varied and manifested by the large SD in serum 
sICAM expression at 72 hr.  Despite the fact that all patients presented to the operating room 
with the typical co-morbidities associated with cardiac disease, patient response to surgery and 
CPB was observably wide-ranging. Interestingly, the SD seen in the PMEA group was also quite 
large at 6 hr. Whether or not this is a relevant observation due to the BCC PMEA is difficult to 
determine.  
Expression of sVCAM-1, sICAM, sE-selectin and sL-selectin confirms previously established 
patterns of expression for patients undergoing CPB (Blume, 1997; Galea, 1998; Wei, 2003; 
Pasnik, 2004). Not surprisingly, preoperative serum sICAM, sE-selectin and sL-selectin levels in 
our older cardiac patients were higher than the levels reported for normal healthy controls 
groups.  
 
4.6.4 Comparison BCC Effect on Release of Soluble Adhesion Molecules 
There were few significant differences in SAM release between the BBC and the uncoated 
control group. sICAM concentrations were significantly different in the control group  from 
baseline to 6 hr compared to non-significant changes in all the BCC groups. Additionally, sL-
selectin levels were significantly lower at 6 hr compared to baseline in all the BCC groups unlike 
the control group where the mean fall from baseline to 6 hr was less pronounced. The lower 
mean serum levels of sL-selectin measured in the BCC groups at 6 hr compared to the uncoated 
control group demonstrates the protective effect of the BCC resulting in decreased activation and 
shedding of this SAM from the leukocyte thereby enabling future leukocyte extravasation into 
surgically disrupted tissues only where needed.  
When looking at group differences, sL-selectin levels at 6 hr were significantly higher in the 
control group when compared to mean levels in the Bioline™ and Trillium™ BCC. Bioline™ 
and Trillium™ BCC coatings are both made with heparin. These results may indicate that 
heparin-based coatings may be more effective in preserving neutrophil adhesiveness. 
Unfortunately, differences between the BCC groups and the control group were no longer 
evident at seventy-two hr. These results might indicate that BCC, designed to decrease the 
inflammatory response consequent to the artificial environment of CPB might indeed be 
successful at doing so but that this effect is limited.  
 
4.6.5 Comparison of BCC Effect on Renal Function and Volume Retention  
BCC group results were no different from the control group in regards to postoperative kidney 
function parameters such as serum urea and creatinine. A significant difference was found in the 
phosporylcholine-coated group alone between baseline and 6 hr serum creatinine levels. Very 
significantly, the pressure drop across the primox oxygenator was excessively higher than in any 
of the other oxygenators tested. As previously mentioned, high changes in pressure are correlated 
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with increased levels of hemolysis. Increased levels of hemolysis may have resulted in the 
augmented short-term decrease in renal function over and above the usual deterioration 
observed. The CPB circuit, and particularly oxygenator design may be a more important 
consideration when it comes to postoperative renal function then whether or not the CPB has a 
BCC. 
No significant difference was found in postoperative weight (fluid) gain between the control 
group and the BCC groups demonstrating, once again, the limited effect the BCCs have in 
attenuating inflammatory response. Of note the PMEA group had the greatest 6 hr weight gain of 
all the groups. This is a relevant finding, considering PMEA had significantly low postoperative 
ASEMT scores and the highest incidence of AF. 
 
4.6.6 Comparison of BCC Effect on Bleeding and Transfusion Requirements   
Although the need to transfuse cardiac surgical patients has been greatly reduced since the 
days before permissive hemodilution became an accepted practice, CPB-assisted cardiac surgical 
patients still frequently require RBC transfusions perioperatively due to anemia. These patients 
may then go on to require additional platelet and plasma transfusions post-CPB as well. The risks 
involved with receiving a blood transfusion are well known (Hajjar, 2010) and all measures were 
taken to reduce this risk.  
In this study, 38% of all patients received a RBC transfusion, 3% received plasma and 13% 
received platelets at some point during their peri-operative phase. No significant transfusion 
differences between patients in the control group and patients in the BCC groups where found. 
This is a different finding from that of Ranucci et al. (2009), (a systematic review) which 
concluded that BCCs reduce the risk of RBC transfusions. Unfortunately, the widely varying 
antifibrinolytic administration in this study may have concealed any benefit the BCCs might 
have realized.  
 
4.6.7 Comparison of BCC Effect on Preventing AF  
Significantly elevated levels of sVCAM-1 were found at baseline in patients who went on to 
develop AF postoperatively. These levels were still significantly elevated at 6 and 72 hr. These 
results do not agree with results of Cosgrave et al. (2005). Their study of 149 patients compared 
SAM levels at baseline and at 72 hr between patients who developed AF postoperatively and 
those that did not. No significant differences were observed between the two groups in their 
study though preoperative and postoperative sVCAM-1 levels were higher in patients who went 
on to develop AF. Thirty-seven percent of patients in their study went on to develop new onset 
AF compared to twenty-three percent in our study. Incidence of postoperative AF was not 
different in the control group compared to patients in the BCC group, however, forty-two percent 
of patients in the PMEA group developed postoperative AF. Although this result is not 
statistically significant, it is clinically and alarmingly relevant. AF contributes to postoperative 
morbidity and mortality experienced by patients who have undergone CPB-assisted cardiac 
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surgery. PMEA-coated circuits increasing the inflammatory response and incidence of AF would 
be the opposite clinical response one would hope for.  
 
4.6.8 Comparison of BCC Effect on NCD  
 
Upon examination it was found that patients in the PMEA and Trillium™ BCC groups had 
significantly worse ASEMT scores at 72 hr compared to their baseline scores. Though not 
statistically significant, the increased incidence of AF and in ICU length of stay found in the 
PMEA group likely contributed to the observed decrease in postoperative ASEMT scores.  
Nothing could be found to explain the decreased postoperative ASEMT scores in the Trillium™ 
BCC group. Previously published comprehensive neurological examinations comparing pre and 
postoperative CPB-assisted cardiac surgical patients, have demonstrated subtle, but consistent 
short-term postoperative neurocognitive deterioration, which would agree with the results of the 
patients in this study. By far the most surprising finding of the study might be that ASEMT 
scores where higher postoperatively compared to preoperatively in the uncoated control group 
alone. These results might indicate that BCC are not protective at all and may in fact be harmful. 
Alternatively, a learning curve in researcher/patient communication may also have been 
responsible for these uncharacteristic findings as this was the first group in which the ASEMT 
was used in this study.  
 
4.6.9 Comparison of BCC Effect on ICU and Hospital Length of Stay   
BCC were unable to improve ICU and hospital length of stay compared to patients who 
underwent CPB with uncoated circuits. The results from this study are different from the finding 
of Ranucci et al. (2009). Their systematic review of BCC technology involving 36 RCT and 
4360 patients showed significantly improved ICU length of stay for patients undergoing CPB-
assisted cardiac procedures employing BCC vs uncoated circuits.  Often, large numbers of 
patients must be used to detect subtle differences in outcomes. Clinical and laboratory outcome 
differences may not have translated to improved clinical outcomes such as ICU and hospital 
length of stay in this study due to the many variables influencing postoperative recovery which 
were uncontrollable.  
 
Differences between the groups in the present study might have been obvious had the correct 
outcome parameters been studied. Measuring postoperative usage of cardiac ionotropes and left 
ventricular contractility, are but two additional parameters, which may have detected clinical 
differences between the groups.  
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5 LIMITATIONS OF THIS STUDY   
Type II errors may have influenced many of the results in this study. Costs associated with the 
purchase of EIA kits for serum analysis limited the number of patients included into each group. 
Larger group sizes would likely have resulted in the same statistically significant findings as 
demonstrated in the previously published study by Ranucci et al. (2009) and Marcoux et al. 
(2009). Marcoux et al. (2009) found that when all 181 original patients were included for 
analyses, more time was spent in ICU by patients in the PMEA group. In the present study, this 
difference was not significant. Additionally, in the present study, no gender-based outcome 
differences were observed when the 9 females were compared to the 9 males in the control group 
unlike the significant differences found when all 101 patients were compared. 
 
Much effort was made to homogenize the perioperative experience for all patients. Even the 
three cardiac surgeons and four perfusionists were analyzed in order to rule out their 
contributions towards outcomes comparison results. Being as it may, certain variables could not 
be accounted for, nor controlled. Antifibrinolytic administration throughout the study was never 
standardized. Dosing was inconsistent, as was time of administration. Additionally, one of the 
antifibrinolytics, aprotinin, was removed from market midway through the study due to results 
from an ongoing systematic review demonstrating a small increase in postoperative renal failure 
and death associated with its administration (Fraser et al. 2008).  
 
Had this study been a blinded, prospective, randomized control trial, rather than a prospective 
cohort study, the resulting data would have been considered more robust statistically speaking. 
Randomized control trials are the gold standard in study design. A prospective cohort study was 
chosen here because it added an element of patient safety.  Repeatedly setting up and using the 
same CPB circuit 36 times in a row before switching to the next manufacturer’s BCC meant 
familiarity with the CPB circuit was possible. Familiarity and routine are elements shown to 
improve patient safety and outcomes within the busy, critical and at times stressful environment 
of the cardiac operating room (Kurusz et al. 1990).  Storage and delivery of enough BCC to 
allow for randomization would have been extremely difficult, if not impossible, in this local 
circumstance. 
 
Finally, the present study did not consider the effect of BCC on complement activation. In a 
study by Fukutomi et al. (1996), decreased complement activation was demonstrated when a 
heparin-coated BCC was compared to an uncoated circuit. Future comparison of complement 
activation between all the BCC included in the present study may yield significant differences 
between the groups and the uncoated circuit despite the fact that the clinical outcome parameters 
measured here were not different. 
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6 CONCLUSION 
The mandate of BCC development is to attenuate the well-documented and repeatedly 
demonstrated inflammatory response consequent to the contact of blood with artificial CPB 
surfaces. This broad based inflammatory response is linked to many, concurrent post-CPB 
morbidities, including NCD, AF, respiratory failure and renal dysfunction of variable degrees. 
These complications contribute to prolonged ventilation times, ICU admissions and 
postoperative hospital length of stay.  
 
Four clinically approved and widely used BCC’s were studied and compared to an uncoated 
control group in patients undergoing routine CPB-assisted cardiac surgery at a single institution.  
 
On the basis of the clinical parameters assessed, the lone significant positive clinical outcome 
parameter detected was the resultant drop in platelet transfusions amongst females in the BCC 
group. On the basis of the laboratory parameters assessed, the significant difference seen 
(sICAM and sL-selectin) between the coated and uncoated groups at 6 hr was no longer apparent 
72 hr postoperatively. Few differences were noted among the four BCC groups.  
 
In regards to postoperative arrhythmias, patients who developed AF postoperatively seemed 
predisposed to do so as inflammatory marker sVCAM-1 was significantly higher in these 
patients at baseline, and remained so at 6 and 72 hr. 
 
In this study, BCC resulted in a modest short-term attenuation of the inflammatory response. 
Decreased platelet transfusions in females, was, the only detectable improvement in observed 
clinical outcomes. Despite the flaws in study design associated with antifibrinolytic 
administration, the results of this study showed the limited beneficial impact of BCC technology. 
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